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ABSTRACT

EVALUATION OF ISPE FOR INHIBITOR DESIGN IN THE
NON-MEVALONATE PATHWAY
Katarzyna B Hoerchler, M.S.
Department of Chemistry and Biochemistry
Northern Illinois University, 2018
Timothy J. Hagen, Co-Director
James R. Horn, Co-Director

There is an urgent need to discover new antibiotics to combat the emergence of drug
resistant bacterial infections and emerging pathogen threats to security.
Novel antibiotics that target unique pathways different from existing therapies are promising
targets. The non-mevalonate pathway (MEP), which was discovered in the 1990’s, is essential
for most bacteria, plants and apicomplexan parasites. Inhibition of the non-mevalonate is an
attractive pharmaceutical target, since it is not present in mammals. Many compounds have
surfaced as potential inhibitors, but none have made it to market. This thesis investigates the
fourth step in the MEP pathway involving the enzyme 4-diphosphocytidyl-2-C-methyl-Derythritol kinase (IspE) from Escherichia coli (Ec), Burkholderia thailandensis (Bt), and
Mycobacterium abscessus (Ma).
The initial aim of this study was to identify in vitro conditions that stabilize the IspE
enzyme and to identify interactions within IspE’s CDP-ME and ATP binding sites that contribute
significantly to the binding energetics. The conditions that best stabilized the enzymes were
investigated with temperature melts using differential scanning fluorimetry and circular
dichroism. All three IspE species displayed melting temperatures (Tm) that heavily depended on

pH, with Tm values dropping significantly with pH values less than 5.0. All three species
fpreferred a reduced environment with high salt content, along with the presence of the metal cofactor Mg2+. These conditions were used to evaluate the binding thermodynamics of the
substrate/co-factor derivatives with IspE using isothermal titration calorimetry. Results showed
that the loss of phosphate groups on ATP most significantly impacted the binding constant. This
suggests that the phosphate binding loop plays an important role in ligand binding. Targeting this
region with small molecule compounds may help improve IspE inhibitor potency. Also, a
significant thermal shift of 10°C with bound CMP to MaIspE suggests hydrogen bonding to
SER147 contributes significantly to substrate binding.
Isotopically-labeled CDP-ME was also synthesized enzymatically for future
characterization of the IspE enzyme by NMR. It can be utilized to monitor conversion of
substrate to product and for assay development.
Finally, 4-quinazolinone compounds were evaluated as potential inhibitors of IspE
activity. However, 4-quinazolinone compounds have been hypothesized to inhibit either IspE or
the auxiliary enzyme luciferase, which is a downstream coupled enzyme in certain IspE assays.
This study found the compounds did not inhibit the luciferase and could in fact be potent IspE
inhibitors. The IspE inhibition assay did not reproduce all IC50 values of various reference
compounds which indicate that further investigation is necessary.
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CHAPTER 1

INTRODUCTION
The years predating antibiotic use were prone to high mortality rates from infections
easily prevented today. Furthermore, the discovery of penicillin by Sir Alexander Fleming in the
1920’s allowed major advances in the field of surgery.1 Since then, numerous classes of
antibiotics have been developed to inhibit cellular processes within infectious species. While it
was originally believed that antibiotics would cure all infections, antibiotic resistant strains soon
followed. Furthermore, a reliance on the idea that alternatives would always exist resulted in low
investment into new antibiotics.2 As years went by, options have become limited for people
suffering from antibiotic-resistant bacterial infections. Continuing down this path could put us
back into the pre-antibiotic era with catastrophic results for the human race.3 Fortunately, the
threat has been recognized and efforts to develop novel anti-infective agents has increased.
Shortly after penicillin was released to market, bacteria began showing signs of antibiotic
resistance. This pushed research efforts toward the discovery of other beta-lactam derivatives.
These efforts lead to the discovery of methicillin; however, within the same decade, cases of
methicillin-resistant Staphylococcus aureus were reported.1 With the spread of this infection,
patients became susceptible to sepsis.4 As years went by, vancomycin was introduced as the cure
for methicillin-resistant strains and was believed to treat any bacterial infection. As with previous
antibiotics, vancomycin resistance also emerged. In turn, efficacy of marketed antibiotics has
undoubtedly been attenuated by resistant-strains of bacteria. Factors such as over prescription of
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antibiotics, overuse by both patient and in livestock treatment2, and the general lack of new and
novel antibacterial drugs all contribute to the growing threat of antibiotic resistant infections.

Targeting Life-Essential Cellular Processes in Infectious Species
Novel antibiotic drug discovery and development benefits from an understanding of the
cellular processes that existing antibiotics disrupt or target. They also benefit from knowledge
regarding the mechanisms that bacteria use for resistance. Bacteria are characterized as Gramnegative or Gram-positive in which the former contains an extra outer membrane. Notably, the
presence of the outer membrane in Gram-negative bacteria, such as E. coli, are more likely to
develop resistance. Current antibiotics target processes involved with the synthesis of DNA,
RNA, the cell wall, and proteins.5 In the first example, DNA topoisomerases are targeted to
inhibit strand breaking and forming when it comes to supercoiling DNA during homeostatic
functions. These include the quinolone family of compounds like ciprofloxacin.6 The Rifamycin
class of compounds bind to actively transcribing RNA polymerase to inhibit synthesis of RNA
itself.5 The third target, cell wall biosynthesis, is inhibited by β-lactams such as penicillin and
vancomycin. β-lactams inhibit peptide bond formation within the peptidoglycan layer while
glycopeptides like vancomycin inhibit this process by intervening in its synthesis.7 Lastly, the
broadest class of antibiotics target protein synthesis. They are classified as either inhibitors of the
50S or 30S subunit of the ribosome. The former can block translation initiation or even the
translocation of peptidyl tRNAs to the next codon. The latter can function to interrupt access of
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aminoacyl- tRNAs to ribosome itself.5 In general, the new antibiotics introduced in the past two
decades are modifications to existing drugs that target these known mechanisms of action.

Pathways Organisms Take to Combat Antibiotics

Drug resistance emerges when bacteria prevent a drug agent from performing its intended
function by employing various mechanisms. In general, bacteria are able to prevent access of the
drug, alter the binding site targeted by the compound, or modify the drug in certain ways.8–11
Small compounds travel into the cell interior by use of porins or diffusion. Hydrophilic
molecules use the former while hydrophobic ones diffuse across the lipid bilayer. To prevent
access into the cell, porins along the cell wall cease to exist or are replaced with ones with higher
specificity.8 An example is the genetic mutation induced by exposure to carbapenem of bacteria
present in the Enterobacteriaceae family. This mutation to the porin-encoding region of a gene
causes loss of permeability of the drug.12 Furthermore, instead of blocking access to a drug, some
bacteria express proteins encoded by specific genes to generate efflux pumps. These actively
transport the invading molecule out of the cell. An example would be the active transport of
tetracycline out of the cell.13 As far as binding site alterations go, inadequate binding interactions
deem antibiotics ineffective. An example would be the loss of affinity for macrolides and
lincosamides to their active site near the new peptide exit terminal on the 50S subunit of
ribosomes. A post-transcriptional modification of an adenine residue within ribosomal rRNA is
dimethylated to prevent binding.13 Lastly, modification of the chemical structure of an antibiotic
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is seen in the hydrolysis of β-lactam drugs like penicillins and cephalosporins by various βlactamase enzymes.8 All in all, new drug and pathway targets are in need to combat known
mechanisms of antibiotic resistance.

The Drug Discovery Process

The discovery of a new drug is a long, complex, arduous and expensive process. It takes
approximately 12-15 years for a drug to come to market with a total cost $1.2-1.8 billion.14 At
the beginning of this process, is the selection of the target. There must be a strong correlation
between the target and the disease with confidence that target modulation will result in efficacy.
The target must also be druggable.15 There must be a robust assay in place that will allow for
screening of compounds against the target. The assays must be reliable and reproducible. Once
a target and an assay are established screening of compounds can begin. During the screening
process hit compounds, from a library of compounds, may be identified. For an enzyme
inhibition assay hit compounds typically have a potency, as measured by equilibrium
dissociation constants, ranging from 5 µM- 100 nM.15 A hit compound is further developed into
a series that defines structure-activity relationships within the target and the specific molecule.16
The structure activity relationships (SAR) involved rational structural changes to compounds that
results in logical changes to activity (i.e., potency) validated target. At that point, a hit may
become a lead series of compounds. Prior to becoming a drug candidate, a lead compound must
display drug like properties which include; selectively for the target and sufficient potency to
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elicit the desired response, possess adequate biodistribution and bioavailability in live animals,
and pass a thorough evaluation of toxicity in animals.17 At this point a clinical candidate may be
selected and an IND (Investigation New Drug) application is submitted to the FDA for clinical
development. Only one in 10 compounds that enter the initial clinical trial will ever reach the
market as an approved drug. There are three major phases of clinical trials in which the drug
candidate must show safety and efficacy against the disease. The clinical trials may take 6 to 13
years and eventually involve testing in thousands of patients. After successful completion of the
clinical trials, a NDA (New Drug Application) is submitted to the FDA which must approve
before it can become a drug. This could take 6 months to two years.
Hit compounds come from many sources. Such compounds can mimic the natural
ligand/substrate or be a derivative of a substance known to interact with the target. Compounds
can also originate from random screening, fragment-based screening, or computational
approaches. Target identification and validation is an important step. Bioinformatics is
frequently used to identify targets. This includes evaluating genomic data and information
pertaining to gene expression, proteomics and RNA expression levels in both normal and
diseased states.15 Once a target has been identified, it must be validated as an essential/critical
component of a pathway. Animal models, gene knockouts, gene manipulation or monoclonal
antibodies can be used for assessing a potential target.15 Once identified as a key contributor, it
serves as a potential target for inhibitor screening.
Prior to compound screening, compounds are first evaluated by guidelines developed
thoughout the years. One of the most well-known set of guidelines comes from an article
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published in 1996. Christopher A. Lipinski 18 summarized physiochemical properties found in
active pharmaceuticals on the market. More specifically, they defined parameters that optimized
solubility and permeability of compounds. The rules state a compound will show poor absorption
and permeation within the body if there are more than 5 hydrogen bond donors, more than 10
hydrogen bond acceptors, if the molecular weight is greater than 500, and if LogP is greater than
5. Log P is a partition coefficient that describes lipophilicity of a molecule. The higher the value,
the more soluble it is in organic solvents. This is important as highly lipophilic molecules can
compromise bioavailability, be absorbed into fat making it difficult to eliminate from the body,
and effect bypass through certain barriers in the body.19 These criteria describe a compound that
is categorized as a drug-like molecule. Another set of guidelines published by Veber et. al.
determined if a molecule had fewer than 10 rotatable bonds and a low polar surface area, it
showed good bioavailability.20 There are numerous guidelines and in silico tools that are used to
assess whether the compounds are drug like. The concept is to weed out poor starting points
early to avoid poor choices.
Another concept utilized in drug discovery is assessing druggability of a target. This
typically describes how well a protein target can be inhibited.21 More specifically, it describes
the ability of that target to bind inhibitors with optimal absorption, permeability, and potent
binding affinity. In other words, it scores the target on the likelihood that an organic compound
will . Furthermore, other concepts develop like drug-likeness by Ajay et al.22 lead-like molecules
by Teague, et al.23 aid in the drug discovery process. Lastly, specific groups on small molecules
can be categorized as privileged structures or toxicophoric groups.14 The first describes moieties
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like indoles and purines that positively interact with diverse targets while the latter are groups
shown to negatively interact, and, as the name suggests, are toxic to humans. An example of
these would be electrophilic epoxides and chelating agents towards metals such as imidazole
groups. In summary, this description of concepts is by no means exhaustive however, have aided
in the discovery of drugs currently on the market.
Initial screening strategies lead to the identification of a hit molecule. These screens
include high throughput, focused screening, fragment screening, structural aided drug design,
virtual screening, physiological screening, and NMR screening.15 As the name suggest, a high
throughput screen involves testing large libraries of compounds against a specific target. This
method can include both focused and fragment screens. The first evaluates compounds with
similar structures to ones previously found to inhibit a class of targets (i.e kinases) while the
second uses smaller molecular weight compounds with weak potency. The hope for the latter is
that with weak binding, additional functional groups can be built upon that core structure to
improve interactions with the target. The next two involve computational methods that evaluate a
crystal structure of a protein to design molecules (structural aided drug design) which can be
further docked to an enzyme. These docked compounds are virtually screened for fit and
predicted affinity. Furthermore, physiological screens evaluate effect of a compound on
biological tissues while NMR screening evaluates fragments for weak to moderate interactions.
All in all, once a lead molecule is identified it enters the lead optimization process of drug
discovery. At this point parameters such as potency, selectivity, absorption, distribution,
metabolism, and excretion (ADME) of the molecules are improved.14 If a compound is able to
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pass all of the filters in may advance in the preclinical pipeline. The research focuses on assay
development and screening a target for hit molecules.

Lead Discovery of Enzyme Inhibitors Requires a Fully Functioning Assay

Hit compound discovery requires a valid assay to assess inhibition of the enzyme. Such
assays must be scalable, as high throughput screening is necessary when testing millions of
potential compounds. Once hit compounds are identified, they are expanded to determine
structure-activity relationships within the active site. Expansion of compounds involves
modifying the structure to determine which points contribute favorably/unfavorably to the
binding potency. The ability to possess stable and pure target enzyme, along with general
knowledge of the enzyme’s kinetic parameters, such as Km and kcat, aid in assay development.24
Kinetic parameters can confirm batch-to-batch activity and are used to calculate optimal
concentrations of substrate and co-factor reagents used in the assay.24,25 Furthermore, organic
solvents such as DMSO are typically used to enhance compound solubility, so the target
enzyme’s activity must be tested in the presence of such solvents.24,26,27 The concentration of
substrate and cofactors is key to identifying inhibitors, particularly inhibitors with low binding
affinity. The concentration of substrate/cofactors should be kept at a level where turnover is
relatively slow to improve sensitivity of the assay against potential inhibitors. Other conditions to
consider when developing an assay are detection methods, whether direct or indirect detection,
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and choosing either a continuous or quenched reaction method. Each have their advantages, so
methodical development is needed prior to establishing an assay for high-throughput screening.25

Targeting the Non-Mevalonate Pathway

Isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) are
phosphorylated 5-carbon units metabolically produced by either the mevalonate or the nonmevalonate pathway. They are essential building blocks for compounds used in various cellular
processes such as transcription, post-translational modifications, cell wall biosynthesis, electron
transport, photosynthesis, intracellular signaling, secreted defense mechanisms, and protein
degradation28. The mevalonate pathway was first discovered in the mid-1900s and was believed
to be the sole pathway of all organisms in the production of isoprenoids. It was not until the early
1990’s that Rohmer and Arigoni29,30 investigated inconsistencies when studying the mevalonate
pathway, revealing the presence of the non-mevalonate pathway. The production of isoprenoids
in most bacteria and parasitic Apicomplexa species come from this pathway while animals,
fungi, archaea, and some bacteria use the mevalonate pathway. Plants, in turn, compartmentalize
each pathway in different regions of the cell.28 Many infectious organisms that are harmful
human pathogens survive using the MEP pathway, which includes the species Mycobacterium
tuberculosis, Plasmodium falciparum, and Staphylococcus aureaus.31 This makes the MEP
pathway a potential pharmaceutical target, as potential non-specific interaction with host
enzymes are eliminated. Notably, neither pathway shares the same proteins (figure 1-1).
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Figure 1-1. Two major pathways that form isoprenoids. The mevalonate and non-mevalonate
pathways utilize different enzymes to synthesize isoprenoid pre-cursors DMAPP and IPP.
The precursors required by each pathway are different metabolic compounds. The
mevalonate pathway is initiated through an influx of acetyl-CoA, while the first enzyme of the
non-mevalonate pathway recognizes pyruvate and glyceraldehyde 3-phosphate.28 This initial
reaction proceeds by the thiamine diphosphate dependent enzyme 1-Deoxy-D-xylulose 5phosphate synthase (DXS). It catalyzes the reaction by activating the TPP thiazolium ring to
attack the carbonyl carbon of pyruvate and direct it towards G3P to form DOXP.32 This
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compound is further reduced to MEP through a NADPH-dependent reaction by IspC.
Fosmidomycin, an IspC inhibitor in clinical trials, has been shown to cure malaria in mice, but
lacks sufficient potency in clinical trials.33,34,35 In the next step, IspD catalyzes the transfer of the
cytidylyl group from CTP to MEP to form CDP-ME. IspE further phosphorylates the C2
hydroxy group of CDP-ME to form CDP-MEP. IspF then cyclizes the product to form MEcPP.
Lastly, the inorganic iron-sulfur co-factor utilized by IspG and IspH reduces the cyclized product
to the final products, IPP and DMAPP.28

Targeting IspE for Drug Development

In 1999, Holger Lüttgen et al. published a study which first identified IspE as the
downstream enzyme following IspD in the non-mevalonate pathway.36 A study was performed to
identify the presence of the ychB (IspE) gene in certain bacteria, and plants along with the
previously discovered enzymes of the MEP pathway. Using thin-layer chromatography, NMR
and isotopically labeled substrate, evidence of ATP-dependent phosphorylation of the 2-OH
group on CDP-ME was revealed.36 Further research by Tomohisa Kuzuyama37 et. al. confirmed
the function of the ychB gene and further characterized its product CDP-MEP. In 2003, the first
crystal structures were obtained (PDB: 1UEK, 1OJ4).38,39 IspE possesses structural features
belonging to the GHMP superfamily. This group includes galactokinases, homoserine
kinases, mevalonate kinases, and phosphomevalonate kinases (termed GHMP). Conserved
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motifs found in this class include a glycine rich phosphate binding loop and a characteristic α/β
fold domain that surrounds the active site (See figure 1-2).

Figure 1-2. GHMP conserved motifs in EcIspE. Monomer subunit of EcIspE displaying GHMP
conserved motifs (blue) with CDP-ME (tan) and ATP (pink) in close proximity. EcIspE
(PDB:1OJ4).39
The enzyme contains five regions that participate in substrate and co-factor binding. As
seen in figure 1-3, these regions are specific towards adenosine, methyl-erythritol, cytidine, and
the phosphate groups. The small hydrophobic pocket that is also highlighted plays a key role in
inhibitor binding as discussed in later sections. It should be noted that only the methyl group on
the methylerythritol moiety of CDP-ME occupies this hydrophobic region.38
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Figure 1-3. Key binding site residues of IspE. Important residues highlighted participate in
either substrate or co-factor binding sites. Adopted from Mombelli.40
Unlike most GHMP proteins, IspE is believed to be a monomer in solution.28 However,
two published structures of EcIspE (PDB: 1OJ4, 2WW4) show a potential homodimer structures
in the crystal lattice (Figure 1-4).39,41 Notably, the arrangement of each homodimer is very
different. The first homodimer (PDB ID:1OJ4) possesses 2-fold symmetry and is co-crystallized
with CDP-ME and a non-hydrolysable version of ATP.39 The second homodimer (PDB
ID:2WW4) lacks that symmetry and is only co-crystallized with ADP.41 This structure shows a
portion of one monomer occluding the active site of the other. Gel-filtration and analytical
ultracentrifugation experiments suggested that only a small amount of EcIspE was present as a
dimer in solution.41 Kalinowska- Tluscik et al. hypothesized that dimer formation was likely an
artefact of crystallization. Three MaIspE crystals have been published and all are classified as
monomers (figure 1-5)42.
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Figure 1-4. Two different crystal structure conformations of EcIspE. Symmetric (left: 1OJ4) or
asymmetric (right: 2WW4) dimers.39,41

Figure 1-5. Crystal Structures of MaIspE. The top (PDB: 4DXL) co-crystallized with ATP and
CMP. The left structure (PDB: 4EMD) co-crystallized with CMP and a sulfate ion while the
right (PDB: 4ED4) co-crystallized with ATP.42
The published structures allowed the identification of important residues involved in
substrate and co-factor binding, as well as the prediction of the catalytic mechanism. Within the
catalytic center, residues Lys10 and Asp141 appear to play the key roles (figure 1-6). The
hydroxyl group in the second position of the methylerythritol tail participates in hydrogen
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bonding interactions with these residues to catalyze its own phosphorylation. While the
negatively charged aspartate abstracts the proton, the positively charged lysine residue directs the
nucleophilic attack of the deprotonated oxygen onto the γ-phosphate of ATP.
.

LYS 10

ASP 141

Figure 1-6. Catalytic center of EcIspE. Asp141 and Lys10 coordinate the nucleophilic attach on
the γ-phosphate of ATP.
The published structures of IspE have aided the drug discovery process. Each co-crystal structure
with ATP reveals a unique syn-conformation. This deterred using this site for drug development
while the substrate binding site was deemed more druggable. Approximately 30 potential
inhibitors have been published over the past years and are summarized below.

Known Inhibitors of IspE

Since the initial discovery of the non-mevalonate pathway step catalyzed by IspE, there
have been numerous publications of potent compounds that inhibited the enzyme at micromolar
concentrations. The following section summarizes each publication and highlights important
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findings in each one. A study published in 2007 by Hirsch et al. reported the
first potent EcIspE inhibitors.43 These inhibitors (Figure 1-7) bound the cytidine binding pocket
and the small nearby hydrophobic region. Unlike previous inhibitors of the pathway, these
compounds avoided using phosphate and phosphonate moieties and possessed drug-like
characteristics.44,45 Using an NMR and pyruvate kinase/lactate dehydrogenase-coupled assay, the
most potent compounds were found to possess IC50 values in the single digit micromolar range
(figure 1-7). Computational modeling suggested that residues Leu15, Leu28 and Phe185, within
the small hydrophobic pocket, interacted with the rigid propargylic sulfonamide linker. It is
worth noting that they reported these residues to be highly conserved between
species. Additionally, the tetrahydrothiophenyl ring that interacted with Tyr25 improve potency
as well.

IC50= 6.0 µM
(E.coli) IspE

IC50= 8.0 µM
(E.coli) IspE

IC50= 6.0 µM
(E.coli) IspE

Figure 1-7. Examples of non-phosphate inhibitors of IspE. Chemical structures and IC50 values
of the most potent inhibitors found by Hirsch et al.43
In 2008, a study further improved compound potency, solubility and addressed structureactivity relationships associated with the substrate binding site46. Incorporating larger ring
structures at the cyclopropyl ring position proved detrimental to inhibition potency
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against EcIspE. Furthermore, they solved a crystal structure (PDB ID: 2VF3) to identify crucial
interactions between AeIspE and the small molecule. Key hydrogen bonding interactions were
observed with the sulfonamide moiety and residues Asn11, Tyr31, and Asp130 (figure 1-8). In
addition, the co-crystal structure revealed the cyclopropyl ring lined the small hydrophobic
pocket adjacent to the CDP-ME binding site (figure 1-9).

TYR31

ASP130

ASN11

Figure 1-8. AeIspE hydrogen bonding interactions with sulfonamide derivative.46
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Figure 1-9. Cyclopropyl ring of sulfonamide derivative lines hydrophobic cavity of AeIspE.
Residues LEU14, ILE27, TYR175, and LEU208 highlighted in blue make up that hydrophobic
region.46
Later that year, Crane et al. investigated cytidine derivatives as alternative
inhibitors against EcIspE.47 Their research aimed to target the more hydrophobic regions in the
substrate active site. Compounds found in figure 1-10 inhibited EcIspE at
millimolar concentrations. The cytidine substructure aimed to mimicked CDP-ME placement
within the active site and the presence of a n-butyl substituent induced a less potent response. In
turn, the addition of a carbon to the benzimidazole moiety had no true impact on binding. This
suggested cytidine interactions were more relevant to ligand binding
affinity. Lastly, crystallographic results highlighted the importance of His25, Lys145, Tyr24, and
Tyr175 and their participation in hydrogen bonding and pi-stacking (figure 1-11).
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IC50= 2.0 mM
(E.coli) IspE

IC50= 1.7 mM
(E.coli) IspE

IC50= Inactive
(E.coli) IspE

IC50= Inactive
(E.coli) IspE

Figure 1-10. Cytidine derivative inhibitors. Chemical structures and IC50 values of the most
potent inhibitors found by Crane et al.47

TYR24
LYS145

TYR175

HIS25

Figure 1-11. AeIspE binding site interactions with cytidine derivative.47
In 2009, Hirsch et al. published work demonstrated that derivatized promising inhibitors
against IspE as derivatized as polymer-peptide bioconjugates displayed to improved solubility
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and potency against IspE.48 Specifically, polyethylene oxide polymers linked to a peptide chain
were used to increase solubility of the original compounds. These were utilized with the
previously mentioned sulfonamide compounds (See figure 1-7)43 along with computationally
designed bi-substrate inhibitors. The latter were made to simultaneously occupy both the
ATP and CDP-ME binding sight. To combat this issue, synthetic peptides were tailored
to mediate specific interactions that promoted solubility. A significant improvement in solubility
was observed, without affecting known inhibition potency of compound 1 (figure 1-12). In
addition, compound 2 was observed to inhibit EcIspE at low micromolar levels (figure 1-12).

1
IC50= 8.0 µM with carrier
(E.coli) IspE

2
IC50= 8.7 µM with carrier
(E.coli) IspE

Figure 1-12. EcIspE inhibitors conjugated to biomolecule. Chemical structures and IC50 values
of the most potent inhibitors found by Hirsch et al.48
In 2011, Tang et al. reported novel compounds that inhibited both Escherichia
coli and Yersinia pestis IspE.49. They expanded existing GHMP kinase inhibitors for a structureactivity relationships study and further reported new compounds that arose from an in
silico HTP screen. They used both the Kinase-GloTM luminescence-based and standard pyruvate
kinase/lactate dehydrogenase-coupled assays to assess inhibition. Structure-activity relationships
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were evaluated using nine analogs of compound 1 fourteen others utilizing compound 2 (figure
1-13). These derivatives most closely resembled substrate binding interactions as found through
a substructure search and docking experiments. From that study, compounds 3 and 4 (figure 113) were found to inhibit the enzyme at 8 µM and 7 µM. Furthermore, a computational approach
found novel compounds 5 and 6 (figure 1-13) both containing the tetrahydro-1,3,5-triazine
scaffold, inhibited IspE as well. These compounds showed greater than 40% inhibition at 20 µM
against IspE. Generally, SARs in this study highlighted the important interaction of the inhibitors
with residues Asp141, Phe185, and Tyr25, suggesting these groups provide hydrogen bonding
and pi stacking interactions.

IC50= 18 µM
(E.coli) IspE

IC50= 7.0 µM
(E.coli) IspE

IC50= 5.5 µM
(E.coli) IspE

40% Inhibition @20 µM
(E.coli) IspE

IC50= 8.0 µM
(E.coli) IspE

80% Inhibition @20 µM
(E.coli) IspE

Figure 1-13. GHMP kinase inhibitors and novel compounds inhibit IspE. Chemical structures
and IC50 values of the most potent inhibitors found by Tang et al.49
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Inhibitors targeting the ribose sub-pocket of the CDP-ME active site were described by
Andri P. Schütz et al. in 2012.51 This investigation continued from previous studies involving the
sulfonamide inhibitors.44 Compounds containing cytosine and 2-aminopyridine moieties were
synthesized and evaluated. Results indicated that cytosine containing substituents with fivemembered heterocyclic rings bound with the best potency (IC50: 1.2-2.0 µM) and that all
derivatives with aryl ring substituents in that same position possessed only modest potency (IC50:
190- > 500 µM). These compounds are presented in figure 1-14. Conclusively, when this pocket
is exposed to more aromatic or polar functional groups, potency drops significantly. Another
set of inhibitors targeting the ribose sub-pocket of the CDP-ME active site were published in
2012 by Andri P. Schütz et al.50. This work continued from previous research involving the
sulfonamide inhibitors.43. This time around, they wished to better understand structure-activity
relationships within ribose sub-pocket of the CDP-ME binding site. In turn, using the NMR and
photometric assay previously described for IC50 determinations, compounds containing cytosine
and 2-aminopyridine moieties were synthesized and evaluated. Results indicated
that cytosine containing substituents with five-membered heterocyclic rings bound the best and
that all derivatives with aryl ring substituents in that same position were only modest binders.
These compounds are presented in figure 1-10. Conclusively, when this pocket is exposed to
more aromatic, or soluble and polar functional groups, potency drops significantly.
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IC50= 2.0 µM
(E.coli) IspE

IC50=1.2 µM
(E.coli) IspE

IC50 Range: 190 µM- >500 µM
(E.coli) IspE

Figure 1-14. Ribose sub-pocket derivatives. Chemical structures and IC50 values of the most
potent inhibitors found by Schütz et al.50
A study published in 2013 by Mombelli et al.addressed potency of various imidazoleand benzimidazole-based compounds.40 The cytidine pocket, along with the small
hydrophobic sub-pocket adjacent to the CDP-ME binding site and the phosphate binding region
of ATP were targeted. They found that compounds that occupied the small pocket still displayed
the most potent inhibitory concentration. The incorporation of a derivatized imidazole functional
group containing alicyclic moieties possessed the lowest IC50 values (see compounds 1 in figure
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1-15). In addition, they incorporated functional groups to carbon four on the imidazole ring of
compound 1 to target the phosphate binding loop. The best potency was observed with the
trifluoromethyl derivative of compound 2 (figure 1-15) In hopes of improving potency,
benzimidazole derivatives were synthesized to promote rigidity and better direct pharmacophoric
regions into the p-loop. These compounds possessed similar inhibitory concentrations
(micromolar range). The compounds showing the most promise are inhibitors 3 and 4 below
(figure 1-15). Ligand occupying the hydrophobic sub-pocket promotes the best inhibition
potency while only a minor contribution toward inhibition are observed from interactions with
polar regions of the active site.

IC50 =12 µM
(E.coli) IspE

IC50 =9.9 µM
(E.coli) IspE

IC50 =17 µM
(E.coli) IspE

IC50 =13 µM
(E.coli) IspE

Figure 1-15. Imidazole and benzimidazole derivatives. Chemical structures and IC50 values of
the most potent inhibitors found by Mombelli et al.40
In 2012, Tidten-Luksch et al, developed a new set of non-substrate-like inhibitors.51.
These inhibitors targeted the cytidine binding site. They screened compounds in silico to develop
a pharmacophore that directed interactions towards the catalytic His25 residue. This screen
identified compounds 1 and 2, which are presented in figure 1-16. In addition, the authors
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screened a chemical library using the Promega Kinase-Glo® PLUS kit. They used the
compounds from the computational study as controls and found that compounds 3 and 4 (figure
1-16) inhibited EcIspE at low micromolar IC50 values. To address structure-activity
relationships, the aminothiazoles and pyrrolopyridines, discovered through the virtual screening,
and indole and quinazolinone derivatives, found through the biochemical screening, were
expanded, chemically. These derivatives displayed no improvement in IC50 values. The authors
suggested Asp130 and His25 were important for ligand binding. It is worth noting that the potent
indole and quinazolinone compound (figure 1-16) were rejected from their in-silico screen due to
a high heavy atom count and ring systems. Furthermore, compound 4 was unsuccessfully docked
while compound 3 was only successful docked by allowing conformational changes to the
receptor.

IC50 =160 µM
(E.coli) IspE

IC50 =1.5 mM
(E.coli) IspE

IC50 =19 µM
(E.coli) IspE

IC50 =2.5 µM
(E.coli) IspE

Figure 1-16: Non-substrate like inhibitors of IspE. Chemical structures and IC50 values of the
most potent inhibitors found by Tidten-Luksch et al.51
Finally, a review by Persch et al. discussed various aspects of molecular recognition in
chemical and biological systems.53 In one part, the paper discussed previously identified IspE
inhibitors and emphasized the difficulty in designing inhibitors targeting the enzyme due to the

26

polarity of the active site. As discussed earlier, there is but one small hydrophobic sub-pocket
within the active site that plays a significant role in known inhibitors. It should be noted that the
authors of reference 87 tested compound 4 (figure 1-16) and did not observe IspE enzyme
inhibition inhibit. They hypothesized the auxiliary enzyme in the Kinase Glo® assay, luciferase,
was inhibited instead.

Thesis Overview

This thesis aims to characterize in vitro stability and active site interactions for three
species of IspE, Escherichia coli (Ec), Burkholderia thailandensis (Bt), and Mycobacterium
abscessus (Ma). This investigation identifies conditions that promote IspE stability, which can be
used in inhibition assays. The observed binding energetics of substrate and co-factor derivatives
binding IspE reveal strong interactions that can be used for inhibitor development. In addition,
this study describes and provides a method to monitor substrate conversion through the synthesis
of isotopically-labeled CDP-ME. An IspE assay was also developed and was used to investigate
inhibition of the auxiliary enzyme luciferase within a coupled-assay to characterize potential
false positive inhibitors.

Chapter 2

STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF ISPE FOR USE IN
IN VITRO TESTING
An understanding of how substrate and co-factor recognize IspE can highlight important
interactions that may support inhibitor design. In addition, knowledge of conditions that promote
IspE stability in vitro are needed for downstream inhibitor screening techniques.54. This
information, in early stage inhibitor development, facilitates structure determination, promotes
stable conditions in the presence of organic solvents, improves enzyme storage, and prevents
protein aggregation.55 Once conditions are optimized, protein crystallization, assay development,
and target screening can commence with increased success rates.56 In this work, three different
species of IspE were studied, including Escherichia coli (Ec), Burkholderia thailandensis (Bt),
and Mycobacterium abscessus (Ma) IspE. Figure 2-1 highlights conserved residues between the
three species. E. coli species tend to be harmless to mammals but infections that are resistant to
antibiotics still persist.57 Burkholderia thailandensis is a close relative to Burkholderia
pseudomallei, the infectious agent responsible for melioidosis.58 Infections that can arise from
exposure to Burkholderia thailandensis are pneumonia and septicemia.59 Lastly, Mycobacterium
abscessus is a rapidly growing organism that shows high antibiotic resistance in lung disease.60
Substrate and co-factor binding studies within these three species was evaluated in this study.
Published structures with co-crystallized CDP-ME and ATP derivatives reveal key active site
residues that participate in the native function of the protein. As a kinase, IspE uses ATP to
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phosphorylate CDP-ME to CDP-MEP. To date, sixteen IspE crystal structures have been
published. For this study, three crystal structures of MaIspE and two structures of EcIspE were
available (PDB: 1OJ4, 2WW4, 4DXL, 4ED4, and 4EMD).40,42,43 Each enzyme is co-crystallized
with either co-factor or substrate and their derivatives. Differential scanning fluorimetry, circular
dichroism, and isothermal titration calorimetry were used to optimize in vitro stability conditions
for all three IspE species.

An understanding of substrate and co-factor recognition within

IspE highlights important interactions that could support inhibitor design. Along with this
understanding, conditions that promote stability of enzyme in solution are needed to use it within
large scale screening techniques. A full biophysical characterization can identify conditions that
stabilize the protein in vitro53. This information, in early stage drug development, facilitates
structure determination, promotes stable conditions in the presence of organic solvents, improves
enzyme storage, prevents protein aggregation and generally optimizes technical features
pertaining to a drug target.54. Once optimized, protein crystallization, assay development, and
target screening with a fully functional robust protein or enzyme can commence.55 In this work,
three different species of IspE were studied. These were Escherichia coli (Ec), Burkholderia
thailandensis (Bt), and Mycobacterium abscessus (Ma) IspE. E. coli species tend to be harmless
to mammals but infections that are resistant to antibiotics still persist.56 Burkholderia
thailandensis is a close relative to Burkholderia pseudomallei, the infectious agent responsible
for melioidosis.57 Infections that can arise from exposure are pneumonia and septicemia.58.
Lastly, Mycobacterium abscessus is a rapidly growing organism that shows high antibiotic
resistance in lung disease.59 Substrate and co-factor binding studies within these three species
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was also evaluated in this study. Published structures with co-crystallized CDP-ME and ATP
derivatives shed light on key residues that participate in the native function of the protein. IspE is
a kinase and therefore uses ATP to phosphorylate CDP-ME to CDP-MEP. To date, sixteen IspE
crystal structures have been published. For this study, three crystal structures of MaIspE and two
of EcIspE were available (PDB: 1OJ4, 2WW4, 4DXL, 4ED4, and 4EMD).39,41,42 Each enzyme is
co-crystallized with either co-factor or substrate and their derivatives. Differential scanning
fluorimetry, circular dichroism, and isothermal titration calorimetry were used to optimize in
vitro conditions for all three IspE species. Figure 2-1 highlights conserved residues between the
three species.
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Figure 2-1. Protein sequence homology in IspE. The species Escherichia coli (Ec), Burkholderia
thailandensis (Bt), and Mycobacterium Abscessus (Ma) IspE observed sequence homology was
43%. The red indicates conserved residues while blue shows identical residues. The yellow
highlights differences between the three species.
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Methods

Expression and purification of EcIspE, BtIspE, and MaIspE

The IspE species is this study were obtained from two separate sources. The EcIspE gene
was generously donated by the Dr. Caren Freel Meyers lab within a pET37b expression vector,
containing an engineered antibiotic resistant gene to kanamycin (Figure 2-2). Expression vectors
for BtIspE (Figure 2-3) and MaIspE (Figure 2-4) were obtained from the Seattle Structural
Genomics Center for Infectious Diseases (SSGCID). The reference ID numbers were
MyabA.00725.a.A1.GE30336 for MaIspE and ButhA.00725.a.A1.GE32746 for BtIspE. The
genes were in an AVA0421 plasmid resistant to ampicillin.
EcIspE

An expression vector consisting of the EcIspE gene inserted in the parent pET37b vector
(figure 2-2), was generously donated by Dr. Caren Freel Meyers . See appendix C for annotated
DNA/protein sequence for EcIspE. Initial expression and purification attempts following the
same procedure as listed in the EcIspE expression and purification section below, resulted in low
quantities of IspE with low purity. DNA sequencing of the expression vector revealed an
unexpected stop codon prior to the C-terminal 8xHis-tag. Consequently, QuikChange
mutagenesis was used to convert the stop codon to serine, thereby allowing expression of the
entire EcIspE-8xHIS-tag.
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QuickChange mutagenesis- The reaction was prepared by combining 1 µL of 50 ng
EcIspE dsDNA, 5 µL 10X Pfu reaction buffer, 1 µL(125 ng/µL) of forward
(5'-GGTGCTCGAGTGAAAGCATGGCTCTGTGCAATG-3') and reverse primer
(5'-CATTGCACAGAGCCATGCTTTCACTCGAGCACC-3'), 1 µL of 10 mM dNTP mixture,
and 1 µL DMSO, all brought to a final volume of 50 µL using freshly filtered (Millipore Millex
33 mm PES filter, 0.22 µm) Millipore water. Next, 1 µL of the PfuTurbo DNA polymerase (2.5
U/µL) was added. The thermal cycler and was then run using the cycling parameters presented in
table 2-1. Once complete, the sample was placed on ice to cool for several minutes, followed by
incubation with 1 µL DPN-1 enzyme at 37°C (water bath) for 1 hr. The parent strand is digested
by Dpn1 enzyme that specifically targets methylated and hemi-methylated DNA.61 Freshly
amplified DNA with mutation was transformed into XL1-Blue competent cells for nick repair.62
Several individual clones were sent for DNA sequencing (University of Chicago sequencing
facility). (5'-CATTGCACAGAGCCATGCTTTCACTCGAGCACC-3'), 1 µL of 10 mM dNTP
mixture, 1 µL DMSO, and brought to a final volume of 50 µL using freshly filtered (Millipore
Millex 33mm PES filter, 0.22 µm) Millipore water. Next, 1 µL of the PfuTurbo DNA
polymerase (2.5 U/µL) was added. The thermal cycler and was then run using the cycling
parameters in table 2-1. Once complete, the sample was placed on ice to cool for several
minutes. Then it was incubated with 1 µL DPN-1 enzyme at 37°C in a water bath for 1 hr. The
parent strand is further digested by Dpn1 enzyme that specifically targets methylated and hemimethylated DNA.60. Freshly amplified DNA with mutation was transformed into XL1-Blue
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competent cells for nick repair61 and sent for sequencing to the University of Chicago sequencing
facility.
Table 2-1. Thermocycling program for QuikChange mutagenesis.
Segment
1
2

Cycles
1
16

Temperature (°C)
95
95
55
68

Time
30 s
30 s
1 min
7 min
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EcIspE:MRTQWPSPAKLNLFLYITGQRADGYHTLQTLFQFLDYGDTISIELRDDGDIRLLTPVEGVEHEDNLIVRAARLLMKT
AADSGRLPTGSGANISIDKRLPMGGGLGGGSSNAATVLVALNHLWQCGLSMDELAEMGLTLGADVPVFVRGHAAFAEGV
GEILTPVDPPEKWYLVAHPGVIPTPVIFKDPELPRNTPKRSIETLLKCEFSNDCEVIARKRFREVDAVLSWLLEYAPSRLTGTG
ACVFAEFDTESEARQVLEQAPEWLNGFVAKGANLSPLHRAMLSLEHHHHHHHH
EcIspE:ATGCGGACACAGTGGCCCTCTCCGGCAAAACTTAATCTGTTTTTATACATTACCGGTCAGCGTGCGGATGGTTA
CCACACGCTGCAAACGCTGTTTCAGTTTCTTGATTACGGCGACACCATCAGCATTGAGCTTCGTGACGATGGGGATATT
CGTCTGTTAACGCCCGTTGAAGGCGTGGAACATGAAGATAACCTGATCGTTCGCGCAGCGCGATTGTTGATGAAAACT
GCGGCAGACAGCGGGCGTCTTCCGACGGGAAGCGGTGCGAATATCAGCATTGACAAGCGTTTGCCGATGGGCGGCGG
TCTCGGCGGTGGTTCATCCAATGCCGCGACGGTCCTGGTGGCATTAAATCATCTCTGGCAATGCGGGCTAAGCATGGA
TGAGCTGGCGGAAATGGGGCTGACGCTGGGCGCAGATGTTCCTGTCTTTGTTCGGGGGCATGCCGCGTTTGCCGAAGG
CGTTGGTGAAATACTAACGCCGGTGGATCCGCCAGAGAAGTGGTATCTGGTGGCGCACCCTGGTGTAAGTATTCCGAC
TCCGGTGATTTTTAAAGATCCTGAACTCCCGCGCAATACGCCAAAAAGGTCAATAGAAACGTTGCTAAAATGTGAATT
CAGCAATGATTGCGAGGTTATCGCAAGAAAACGTTTTCGCGAGGTTGATGCGGTGCTTTCCTGGCTGTTAGAATACGC
CCCGTCGCGCCTGACTGGGACAGGGGCCTGTGTCTTTGCTGAATTTGATACAGAGTCTGAAGCCCGCCAGGTGCTAGA
GCAAGCCCCGGAATGGCTCAATGGCTTTGTGGCGAAAGGCGCTAATCTTTCCCCATTGCACAGAGCCATGCTTTCACTC
GAGCACCACCACCACCACCACCACCACTAA

Figure 2-2. EcIspE vector map with protein and DNA sequence.
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EcIspE Expression and Purification- The expression of EcIspE with the C’-terminal
(His)8-tag began with a fresh transformation of the plasmid DNA into BL21-DE3
supercompetant cells. Colonies were grown on Lysogeny broth (LB) agar plates containing 50
µg/mL kanamycin. Next, a single colony was used to inoculate a 5 mL overnight culture
composed of LB broth containing 50 µg/mL kanamycin. The culture(s) were incubated overnight
for no more than 16 hrs at 37°C with shaking (235 rpm). The next morning, a 30 mL sub-culture
(LB/kanamycin) was inoculated with 300 µL of the overnight culture at 37°C with shaking (235
rpm). Furthermore, once the culture reached mid-log phase (OD600 between 0.5-0.8), a 1 L
culture made up of LB broth, 50 µg/mL kanamycin, and 200 mM MgCl2 was inoculated with 10
mL subculture. All subsequent cultures were pre-equilibrated and kept at 37°C with shaking (235
rpm) prior to inoculation to maintain constant temperature. Once the same OD600 level was
reached, each 1 L culture was induced with 1 mM IPTG. The temperature was brought down to
20°C and incubated for 16 hours (overnight). The next morning, the cells were harvested by
centrifugation at 8,000 rpm for 10 minutes. Furthermore, pellet weight was documented, and the
pellets were flask frozen with liquid nitrogen to be stored at -20°C.
During purification, the frozen pellet was re-suspended in 10 mM Tris-HCl pH 8.0 buffer
containing 1 mM DTT. Reconstituted pellets were further lysed by sonication on ice using a
Digital Sonifier 450® (Branson) for six cycles of 20 seconds on/60 seconds off. The lysate was
centrifuged at 16,000 rpm for 20 minutes at 4°C. The supernatant was visually inspected for
precipitate and if present, the sample was centrifuged once more. The supernatant was loaded
onto an HisTrap HP nickel affinity IMAC column (GE Healthcare Life Sciences) using a
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ӒKTAprime Plus (GE Healthcare Life Sciences) fast protein liquid chromatography (FPLC)
systems. The loading buffer contained 50 mM sodium phosphate pH 8.0, 20 mM imidazole, 500
mM NaCl, and 1 mM dithiothreitol (DTT). The column was stored in loading buffer containing
no DTT, so prior to each run, it was equilibrated with 5 column volumes (CV) of loading buffer
containing the reducing agent. The protein was eluted using a gradient elution method over 70
mL (500 mM imidazole, pH 8.0, 50 mM sodium phosphate, 500 mM NaCl, and 1 mM
dithiothreitol (DTT). The fractions containing the EcIspE enzyme were combined, concentrated,
and typically subjected to additional purification using a Superdex 75, 26/60 size exclusion
column (GE Healthcare Life Sciences) using 20 mM TRIS pH 8.0, 150 mM NaCl and 1 mM
DTT. The column was equilibrated with 2 CV worth of the buffer containing DTT prior to each
run. The concentration of protein was determined at each purification step. The concentration
was determined at 280 nm using the extinction coefficient 34,950 M-1cm-1 (Molecular weight:
32,264 Da). Lastly, EcIspE was dialyzed in storage buffer (50 mM sodium phosphate pH 7.0,
150 mM NaCl, 5 mM MgCl2, and 1 mM DTT) concentrated, flash frozen in liquid nitrogen, and
lyophilized for storage in -20°C. An SDS-PAGE gel was run to confirm and validate the
purification protocol.
BtIspE and MaIspE
The two species of IspE that were obtained from SSGCID (figure 2-3 and 2-4), BtIspE
and MaIspE, were expressed and purified using the EcIspE purification procedure, described
above, with only minor modifications. See appendix C for DNA and protein sequence overlay
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for BtIspE and MaIspE. Expression constructs stored as glycerol stocks were used to inoculate
overnight cultures. Expression was carried out in lysogeny broth containing 100 µg/mL
ampicillin. Furthermore, purification was executed using the same buffers at pH 8.0 for BtIspE
and at pH 7.2 for MaIspE. An improvement in MaIspE activity was observed with this minor
adjustment in pH. If the affinity tag was to be cleaved, two additional steps were required. The 6His-MBP-3C protease (supplied by SSGCID) was used to cleave the affinity tag using their
published protocol, with only minor modifications.62 Once the initial IMAC purification step was
complete, an in-solution digest was run overnight. A 1:50 w/w 3C-protease to IspE solution was
prepared and dialyzed in 25 mM HEPES pH 7.5, 500 mM NaCl, and 1 mM DTT buffer. A
second IMAC step was used to isolate cleaved protein from the His-tagged protease and uncleaved MaIspE or BtIspE. Lastly, size exclusion chromatography was performed using the
procedure described above. Molecular weight standard size exclusion runs were also performed
to estimate the molecular weights of the eluted proteins. The concentration was determined at
280 nm using the extinction coefficient 37,470 M-1cm-1 (Molecular weight: 33,865 Da) for
BtIspE and 24,980 M-1cm-1 (Molecular weight: 34,795 Da) for MaIspE.
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BtIspE:MAHHHHHHMGTLEAQTQGPGSMTDTTRSLRDCLAPAKLNLFLHITGRRPDGYHELQSVFQLLDWGDRLHFTLRDDG
KVSRKTDVPGVPEETDLIVRAASLLKAHTGTAAGVDIEIDKRLPMGAGLGGGSS AATTLLALNRLWKLDLPRATLQSLAVKLG
ADVPFFVFGK NAFAEGIGEALQAVELPTRW FLVVTPRVHV PTAAIFSEKS LTRDSKPITITDFLAQQDCN TGWPDSFGRN
DMQPVVTSKY AEVAKVVGWF YNLTPARMTG SGASVFAAFK SKAEAGAAQA QLPAGWDSAV AESLGEHPLF AFAS

BtIspE:ATGGCTCATCACCATCACCATCATATGGGTACCCTGGAAGCTCAGACCCAGGGTCCTGGTTCGATGACCGATACG
ACCCGCTCGCTGCGCGACTGCCTCGCCCCGGCGAAACTGAACCTGTTCCTGCACATCACGGGCCGTCGTCCGGACGGCTA
TCACGAGCTGCAAAGCGTGTTCCAGCTGCTCGACTGGGGCGACCGGCTGCACTTCACGCTGCGCGACGACGGCAAGGTG
TCGCGCAAGACCGACGTGCCGGGCGTACCCGAGGAAACCGACCTCATCGTGCGCGCGGCGTCGCTGCTGAAAGCGCACA
CGGGCACGGCGGCGGGCGTCGACATCGAGATCGACAAGCGACTGCCGATGGGCGCGGGCCTCGGCGGAGGCAGCTCGG
ATGCGGCGACGACGTTGCTCGCGCTCAACCGCCTCTGGAAGCTCGACTTGCCGCGCGCCACGCTGCAATCGCTCGCGGTG
AAGCTCGGCGCCGACGTGCCGTTCTTCGTCTTCGGAAAAAATGCGTTCGCAGAGGGTATCGGAGAAGCGCTGCAAGCTGT
AGAATTGCCGACTCGCTGGTTTCTGGTTGTGACACCGCGGGTTCACGTTCCGACCGCAGCGATTTTTTCCGAAAAATCGTT
GACAAGAGATTCGAAACCCATCACAATTACGGACTTTCTTGCACAGCAAGACTGCAACACGGGATGGCCTGACAGTTTC
GGTCGGAATGACATGCAGCCGGTTGTGACAAGCAAGTACGCGGAAGTTGCAAAGGTGGTCGGATGGTTTTATAATCTGA
CCCCCGCGCGGATGACCGGCTCCGGAGCTAGCGTGTTTGCAGCGTTCAAGAGCAAGGCGGAGGCAGGAGCGGCGCAAGC
CCAACTGCCGGCCGGCTGGGACAGCGCAGTTGCCGAGAGCTTGGGTGAGCATCCACTCTTCGCTTTCGCGTCATAA

Figure 2-3. BtIspE DNA and protein sequence with vector map.
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MaIspE:MAHHHHHHMGTLEAQTQGPGSMVSETVSDWVPTGAVTVRAPGKVNLYLAVGDLRDDGYHELTTVFHAVSLADDV
TVRDADLSIDVVGQGEGTVPTDERNLAWQAAELFADHVGRAPDVSIFINKDIPVAGGMAGGSADAAAVLVAMNELWHAGVP
RRDLHHLAAQLGSDVPFALHGGTALGTGRGEQLATVLARNVFHWVFAFADGGLATPQVFKEIDRLRENGDPPRLAEADELLG
ALAAGDARRLAPLGNELQAAAVSLNPELRRTLRAGESAGALAGIVSGSGPTCAFLCTSADDAVQVSAELAGAGVCRTVRVAS
GPVHGAQVIQGRSDG
MaIspE:ATGGCTCATCACCATCACCATCATATGGGTACCCTGGAAGCTCAGACCCAGGGTCCTGGTTCGATGGTGTCCGAG
ACCGTCTCCGATTGGGTTCCTACCGGCGCGGTGACTGTCCGGGCACCCGGCAAGGTCAATCTGTACCTGGCCGTAGGTGA
CCTCCGTGACGACGGCTATCACGAGCTGACCACGGTTTTTCACGCCGTTTCGCTGGCCGACGACGTGACCGTGCGGGACG
CCGACGTGTTATCGATCGATGTGGTCGGGCAGGGCGAGGGCACGGTGCCCACCGACGAACGCAATCTCGCCTGGCAGGC
CGCCGAGCTTTTCGCCGATCACGTGGGCCGCGCCCCCGACGTCTCGATCTTCATTAACAAGGACATCCCCGTCGCGGGCG
GTATGGCCGGCGGATCCGCCGATGCCGCTGCGGTGTTGGTGGCGATGAACGAGCTCTGGCATGCCGGTGTGCCGCGCCGG
GACCTGCACCACCTGGCCGCTCAACTGGGCAGCGATGTCCCCTTTGCCTTACATGGCGGCACCGCGCTGGGCACTGGCCG
GGGTGAGCAGCTGGCGACCGTATTGGCGCGCAATGTCTTTCATTGGGTGTTCGCCTTCGCCGACGGGGGACTGGCGACGC
CTCAGGTCTTCAAGGAGATCGACCGGTTGCGTGAGAACGGCGATCCGCCGCGGCTCGCCGAGGCGGATGAGCTTTTGGGT
GCGCTCGCCGCCGGGGACGCGCGCCGGCTGGCGCCGCTGCTCGGTAACGAATTGCAGGCCGCGGCGGTCAGCCTGAACC
CCGAATTGCGGCGCACGCTGCGGGCAGGGGAGTCGGCCGGCGCCCTGGCTGGAATCGTCTCCGGATCGGGCCCCACCTG
TGCGTTCTTGTGCACCTCGGCCGACGATGCGGTGCAGGTGAGTGCGGAGCTGGCGGGCGCGGGGGTGTGCCGCACCGTG
CGGGTGGCCAGCGGACCCGTGCACGGCGCACAGGTCATCCAGGGCCGCAGTGACGGCTAA

Figure 2-4. MaIspE DNA and protein sequence with vector map.
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SDS-Page Protocol used to Evaluate Purification Method
Samples were taken throughout the purification procedure to evaluate final purity using
SDS-page electrophoresis. This included samples of crude lysate and post-purified protein.
Samples were loaded onto an Invitrogen Bolt™ 4-12% Bis-Tris Plus gel containing about 10-20
µg of protein per lane. Each sample was treated with either 1x reducing (0.5 M DTT added fresh)
or non-reducing gel loading buffer (0.25% Bromophenol Blue, 50% glycerol, 10% SDS, 0.25M
Tris-HCl pH 6.8) and run at 120 V in SDS-page running buffer (50 mM MES, 50 mM Tris, 0.1%
SDS, 1 mM EDTA pH 7.3). Once complete, the gel was taken out of the casing and rinsed and
soaked with Millipore-purified water three times at 5-min intervals. It was further stained using
GelCode™ Blue Stain Reagent (Thermo Fisher) overnight and de-stained the next day with
purified water.

Thermal Stability Evaluation using Differential Scanning Fluorimetry

Successfully studying an enzyme in vitro requires knowledge of conditions that maintain
stable, active enzyme, which can depend on buffer composition, pH, and salt, as well as a range
of other additives. For example, when developing an inhibition assay, the enzyme must remain
active (ideally) in the presence of DMSO. Effectively screening an enzyme against those
conditions can be done using differential scanning fluorimetry (DSF). It is a low-cost high
throughput screening technique ideal for assessing stability of protein in solution and is widely
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used for this purpose.64,65 Many combinations of buffers at various pH with different stabilizing
agents can be tested. The stability of a protein in solution can be quantified by estimating its
melting temperature (Tm) in different solutions.63,64 The stability of a protein in solution can be
quantified by estimating its melting temperature (Tm) in different solutions. The Tm of an enzyme
is the temperature at which 50% of the protein is folded and 50% is unfolded. As an enzyme is
exposed to increasing temperature, unfolding occurs resulting in exposed hydrophobic regions.
DSF uses a fluorescent probe (SYPRO™ Orange) that specifically interacts with these exposed
hydrophobic surfaces, resulting in a change in fluorescence emission that is related to protein
unfolding. SYPRO™ Orange has an excitation of 470 nm and emission at 570nm.65
A high-throughput study of EcIspE, BtIspE, and MaIspE in changing environmental
conditions was initiated to determine which best stabilized the enzyme. Each sample contained
the buffer system to be evaluated, protein, DMSO, and dye at a final volume of 25 µL. As these
enzymes ultimately were used for inhibition studies, DMSO was included to evaluate DMSO
tolerance. Inhibitors are frequently insoluble at the desired concentration in aqueous solvent, so
DMSO is added to enhance solubility. The final concentrations were 4 µM of protein, 4x
SYPRO dye, and 4% DMSO. The first trial used a range of buffers at 50 mM concentration with
50 mM NaCl. The second trial kept those concentrations constant but included 1 mM DTT and 5
mM MgCl2. The final trial held buffer and additive compositions constant and increased the ionic
strength by adjusting NaCl concentration to 150 mM. The different buffer components used that
were tested at each pH are summarized in table 2-2. The DSF runs were performed on a Bio-Rad
iQ5 Real-Time PCR (Bio-Rad Life Sciences) using a temperature range of 10-95°C at a ramp
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rate of 1°C/min with the fluorescence measured every 0.5°C using an excitation filter of 485/30x
nm and an emission filter at 575/20x nm, respectively. The melting temperature (Tm value) was
determined from the first derivative of the graph of relative fluorescence units vs. temperature.
Substrate and co-factor derivates (figure 2-5), purchased from Sigma Aldrich, were also
evaluated against BtIspE and MaIspE in 50 mM HEPES pH 7.0, 150 mM NaCl, 5 mM MgCl2,
and 1 mM DTT.
Table 2-2. Composition of buffer solutions used in stability screen.
pH
4.0
5.0
6.0
6.5
7.0
7.0
7.0
7.5
7.5
7.5
8.0
8.0
9.0

Composition (50 mM)
Acetate
Acetate
MES
Citrate
Phosphate
HEPES
Tris
Phosphate
HEPES
Tris
HEPES
Tris
Glycine

Melting Temperature Verification using Circular Dichroism

To evaluate the thermostability of MaIspE, circular dichroism was used as a direct
measurement of the protein’s secondary structure. It was tested using 50 mM MES pH 6.0, 150
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mM NaCl, 5mM MgCl2, 1 mM DTT and 50 mM HEPES pH 7.0, 150 mM NaCl, 5 mM MgCl2,
and 1 mM DTT. Twenty micromolar MaIspE was dialyzed separately overnight in each 4 L
buffer. The next morning, the protein was centrifuged at 14,000 rpm for 10 min at 4°C. All
samples were tested using an Aviv Instruments circular dichroism spectrometer model 215 with
the buffer system determined through DSF to promote the best stability. Wavelength scans were
taken at 20°C before and after protein melts from 200-250 nm using a 1 nm bandwidth. A quartz
cuvette with a 1 mm path length was used. A blank run with buffer was measured to subtract
baseline signal and ensure no contaminants were present in the cuvette prior to a run.
Furthermore, temperature denaturation experiments were monitored at 215 nm (pH 6.0) and 210
nm (pH 7.0). These experiments were run over a temperature range of 20 to 100°C at 1°C
increments with a 2 nm bandwidth and 2 second averaging time. Data was analyzed using the
Boltzmann fit in Origin labs.
Substrate and Co-factor Binding study using Isothermal Titration calorimetry

Direct measurement of a binding event can be detected with isothermal titration
calorimetry. This technique allows determination of thermodynamic parameters, such as the
binding stoichiometry (n), binding constant (Kb), ΔHobs, and ΔSobs. The dissociation constant can
be calculated from the inverse of Kb. The measured heat released or absorbed by a reaction is
proportional to the moles of interacting ligand per injection. This relationship is seen in equation
2-1. The difference in bound ligand concentration per injection (∆ ), volume of the injection
( ), and enthalpic contribution define this detected heat.
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=

×∆ ×∆

Eq. 2-1

The differential power required to maintain constant temperature is the raw signal output of an
experiment. This power in µcal/second is converted to kcal/mol of injectant through integration
of the area of each injection peak normalized by the moles of ligand. As binding sites are
increasingly saturated, the power required to compensate for heat change decreases. Dilution
heats, the heat caused from injectant dilution into buffer, must be subtracted from all data points.
The experimental values that can be obtained from a single experiment are ΔH°, Ka, and n,
which can be used to calculate ΔG° and -TΔS°. ITC is highly sensitive and requires accurate
knowledge of the protein and ligand concentration. Protein concentrations were determined with
estimated extinction coefficients calculated by the Pace method66. Most ligand concentrations
were based off dry weight, except for ATP, where the absorption coefficient of 15.4 mM-1cm-1 at
259 nm was used. Each experiment was performed in 50 mM HEPES pH 7.0, 150 mM NaCl, 5
mM MgCl2, and 1 mM TCEP with protein in the cell and ligand in the syringe. All experiments
were performed at 25°C consisting of 28 injections, separated by 240 seconds with a stirring
speed of 307 rpm. The first injection volume was 2 µL and the remaining injections were 10 µL.
The first injection was omitted in data analysis to account for dilution across needle to cell
during equilibration. When necessary, a separate dilution experiment was run by injecting ligand
into buffer only. This titration was subtracted from the original run to account for dilution heats.
Data was further analyzed and plotted using Origin 7.0 with ITC extension supplied by the
manufacturer (Microcal).
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Substrate and co-factor derivates were purchased from Sigma Aldrich and evaluated
against BtIspE and MaIspE. The purity of each derivative was verified through the certificate of
analysis provided by the supplier. These compounds (figure 2-5) were tested using a 50 mM
HEPES pH 7.0, 150 mM NaCl, 5 mM MgCl2, and 1 mM TCEP buffer system.

Figure 2-5. Substrate and Co-factor derivatives analyzed by ITC and DSF. Fragments associated
with CDP-ME and ATP were purchased to evaluate specific interactions within IspE.
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Results

Expression and purification of EcIspE, MaIspE, and BtIspE

Initial attempts to purify EcIspE were unsuccessful due to the presence of an
unanticipated stop codon between the enzyme and His-tag gene. That stop codon prevented the
8xHIS-tag from being translated. Based on DNA sequencing, Quikchange mutagenesis was
successfully performed, replacing the stop codon with a codon for the amino acid serine (figure
2-6). The sequence-verified vector was transformed into BL21-DE3 supercompetent cells and
EcIspE was expressed and purified. The chromatogram of IMAC and size exclusion purification
can be found in figure 2-7. An SDS-PAGE analysis of the post-size exclusion fractions is
presented in figure 2-8, confirmed the presence of a protein band consistent with EcIspE (Mw=32
kDa). Samples from the major size exclusion peak, which is consistent with a solution molecular
weight of 32 kDa, was run in lanes 4-8 (non-reducing) and 11-15 (reducing). Samples of peaks 1
(exclusion limit) and 2 (MW: ~67 kDa) were tested in lanes 4-5 and 11-12, respectively. The
final yield of pure EcIspE was 43 mg of protein per 1 L culture.
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Figure 2-6. C-Terminal/5’ end of EcIspE translation/DNA showing stop codon replacement.
Transformation of stop codon (bottom) to serine residue (top) promoted expression of 8xHIS tag
for affinity purification.

A

B

Figures 2-7. Chromatograms from purification of EcIspE. A) IMAC purification spectra;
Absorbance: 280 nm. B) Size exclusion profile with EcIspE (red) and molecular weight
standards (black); Absorbance: 280 nm. Standards: Blue Dextran at exclusion limit = 2,000 kDa,
Ovalbumin = 43 kDa, BSA = 67 kDa, and Cytochrome C = 12 kDa.
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Figure 2-8. SDS-page of purified EcIspE. Samples include crude lysate (lane 2), IMAC purified
protein (lane 3), size-exclusion purified protein under non-reducing conditions (lanes 4-8) and
size-exclusion purified protein under reducing (lanes 11-15).

BtIspE and MaIspE were successfully purified (figures 2-9 and 2-10). Purification trials
using IMAC and size exclusion buffers at pH 8.0 yielded about 2 mg/ml BtIspE and 0.5 mg/mL
MaIspE. Lastly, eluted peaks corresponding to the molecular weight of both MaIspE (MW: 35
kDa) and BtIspE (MW: 34 kDa) from the size exclusion column were evaluated using SDSPAGE (figure 2-11). The elution profile obtained for both BtIspE and MaIspE showed potential
elution of dimer species at about ~67 kDa.
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A

B

Figure 2-9. Purification chromatography spectra of BtIspE. A) IMAC purification spectra
Absorbance: 280 nm. B) Size exclusion profile with BtIspE (red) and molecular weight standards
(black). Absorbance: 280 nm. Standards: Blue Dextran at exclusion limit = 2,000 kDa,
Ovalbumin = 43 kDa, BSA = 67 kDa, and Cytochrome C = 12 kDa.

A

B

Figure 2-10. Purification chromatography spectra of MaIspE. A) IMAC purification spectra.
Absorbance: 280 nm B) Size exclusion profile with MaIspE (red) and molecular weight
standards (black) Absorbance: 280 nm. Standards: Blue Dextran at exclusion limit = 2,000 kDa,
Ovalbumin = 43 kDa, BSA = 67 kDa, and Cytochrome C = 12 kDa.
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Figure 2-11. SDS-page of purified BtIspE and MaIspE in non-reducing conditions. Lanes 2 and
3 are unrelated protein. MaIspE peaks from SEC are sampled in lane 4 (exclusion limit) and 5
(~35 kDa) while BtIspE SEC samples are in lane 6 (exclusion limit) and 7 (~34 kDa).

Thermal Stability Evaluation using Differential Scanning Fluorimetry

To examine the thermal stability of MaIspE, BtIspE and EcIspE, differential scanning
fluorimetry (DSF) was used to test different buffers and ionic strength, along with the presence
of additives. Trials in 50 mM buffer and 50 mM NaCl, but without reducing agent and MgCl2
did not show appreciable transitions. Consequently, follow up trials were modified to include 1
mM DTT and 5 mM MgCl2. A high initial signal was observed with mild transitions. Subsequent
trials increased the ionic strength, changing the concentration of NaCl to 150 mM. These

51

conditions produced clear transitions. The normalized results are presented in figures 2-12, 2-13,
and 2-14.

Figure 2-12. DSF buffer screen of 4 µM BtIspE. Thermal profile was evaluated in 50 mM
buffer, 150 mM NaCl, 1 mM DTT, and 5 mM MgCl2 (4x dye).

Figure 2-13. DSF buffer screen of 4 µM MaIspE. Thermal profile was evaluated in 50 mM
buffer, 150 mM NaCl, 1 mM DTT, and 5 mM MgCl2 (4x dye).
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Figure 2-14. DSF buffer screen of 4 µM EcIspE. Thermal profile was evaluated in 50 mM
buffer, 150 mM NaCl, 1 mM DTT, and 5 mM MgCl2 (4x dye).

The melting temperatures were determined and compiled in table 2-3. Only protein melts that
displayed a clear transition curve are presented. All species of IspE did not tolerate the Acetate
pH 4.0 buffer. EcIspE and BtIspE were relatively stable within a wide pH range while MaIspE
showed optimal transitions only between pH 5.0 and 7.0. Secondary transitional periods can be
seen in some conditions.
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Table 2-3. Melting temperature of IspE in different buffer systems (n=2).
pH

Composition (50 mM)

EcIspE Tm (°C)

BtIspE Tm (°C)

MaIspE Tm (°C)

4.0
5.0
6.0
6.5
7.0
7.0
7.5
7.5
7.5
8.0
8.0
9.0

Control (Protein in H2O)
Acetate
Acetate
MES
Citrate
Phosphate
HEPES
Phosphate
HEPES
Tris
HEPES
Tris
Glycine

37 (±1)
48.1 (±0.0)
53.5 (±0.2)
53.8 (±0.6)
51.5 (±0.1)
54.2 (±0.1)
52.1 (±0.3)
52.0 (±0.2)
51.6 (±0.1)
51.9 (±0.0)
51.1 (±0.1)

39 (±2)
44.1 (±0.2)
43.5 (±0.4)
41.1 (±0.0)
42.8 (±0.1)
40.2 (±0.2)
41.2 (±0.2)
39.3 (±0.9)
39.1 (±0.2)
37.8 (±0.4)

34.5 (±0.0)
35.6 (±0.4)
40 (±1)
45 (±1)
42.1 (±0.8)
39.1 (±0.0)
-

Melting Temperature Verification using Circular Dichroism

The thermostability of MaIspE was evaluated using circular dichroism in buffer
conditions showing the highest stability in DSF experiments. The buffer systems promoting the
most stable conditions were either 50 mM citrate pH 6.5 or 50 mM phosphate pH 7.0 both
containing 150 mM NaCl, 5 mM MgCl2, and 1 mM DTT. Wavelength scans were taken before
and after thermal melts to confirm the secondary structure and evaluate reversibility. Scans of
MaIspE confirm the presence of mainly β-sheets in the secondary structure (figure 2-15). The
melting temperature was found to be 50°C in a pH 6.0 solution while multiple, small transitions
were observed at pH 7.0 (~40°C and ~85°C). In fact, MaIspE does not appear to have undergone
global at pH 7.0 (figure 2-16). Considerable native signal remains in the post-melt pH 7.0
spectrum (figure 2-15), also suggesting MaIspE may not have fulling unfolded.
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Figure 2-15. Pre and post-thermal melt wavelength scans of MaIspE. MaIspE reversibility was
evaluated at pH 6.0 (left) and pH 7.0 buffer (right).

Figure 2-16. Thermal melt experiment of MaIspE. MaIspE melting temperature (Tm) was
evaluated at pH 6.0 (left) and pH 7.0 buffer (right).
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Substrate and Co-factor Binding study using Isothermal Titration calorimetry
ITC studies were pursued to evaluate the binding thermodynamics for IspE with substrate
and co-factor derivatives. MaIspE and BtIspE were tested against the derivatives found in figure
2-5. The results from BtIspE and MaIspE are listed in table 2-4 and 2-5, respectively. Raw data
from each run can be found in appendix A. With both IspE species, ADP and CDP bound tighter
than any other compound tested. In most cases, the binding event was both entropically and
enthalpically favored. In BtIspE, CMP and cytidine compounds displayed an unfavorable
entropic interaction, but the enthalpic contribution dominated.
Table 2-4. Binding Thermodynamic parameters for BtIspE with CDP-ME and ATP derivatives
at 25°C.
Compound

KD (µM)

AMP-PNP
ATP
ADP
AMP
Adenosine
CDP
CMP
Cytidine

150 (±50)
100 (±20)
48 (±1)
150 (±20)
NB
50 (±10)
100 (±20)
300 (±90)

ΔH (kcal
mol-1)
-1.4 (±0.2)
-2.7 (±0.5)
-4 (±3)
-2.0 (±0.4)
NB
-4 (±4)
-9 (±1)
-6.6 (±0.1)

-TΔS (kcal mol-1)

ΔG (kcal mol-1)

-3.6 (±0.2)
-2.7 (±0.7)
-2 (±3)
-3.1 (±0.5)
NB
-3.7 (±0.5)
3 (±1)
1.7 (± 0.1)

-5.1 (±0.2)
-5.4 (±0.2)
-5.9 (±0.0)
-5.2 (±0.1)
NB
-4 (±3)
-5 (±0)
-4.9 (±0.1)

Table 2-5. Binding Thermodynamic parameters for MaIspE with CDP-ME and ATP derivatives
at 25°C
Compound
ATP
ADP
AMP
Adenosine
CDP
CMP

KD (µM)
60 (±4)
39 (±3)
140 (±6)
NB
38 (±4)
15 (±13)

ΔH (kcal mol-1)
-1.1 (±0.1)
-1.9 (±0.0)
-1.2 (±0.1)
NB
-1.3 (±0.0)
-1.4 (±0.1)

-TΔS (kcal mol-1)
-4.5 (±0.1)
-4.1 (±0.0)
-3.9 (±0.1)
NB
-5.3 (±0.0)
-4.6 (±0.1)

ΔG (kcal mol-1)
-5.7 (±0.1)
-6.0 (±0.0)
-5.2 (±0.1)
NB
-6.5 (±0.0)
-6.0 (±0.1)
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The compounds tested using ITC were further evaluated using DSF in a 50 mM HEPES, 150
mM NaCl, 1 mM DTT, and 5 mM MgCl2 buffer. This buffer system was found to stabilize both
MaIspE and BtIspE during initial buffer screening. Melting temperatures of each compound with
BtIspE can be found in table 2-6 with normalized thermal denaturation curves presented in figure
2-17. The presence of ADP and each CDP-ME fragment separately stabilized the protein about
5°C.

B

A

Figure 2-17. DSF thermal denaturation curves of BtIspE. All in the presence of substrate and cofactor derivatives. A) ATP derivatives B) CDP-ME derivatives.
Table 2-6. Tm of BtIspE in the presence of substrate and co-factor derivatives.
Compound
No Compound
AMP-PNP
ATP
ADP
AMP
Adenosine
CDP
CMP
Cytidine

Tm (°C)n=2
41.2 (±0.0)
43.1 (±0.3)
45.6 (±0.8)
46.4 (±0.6)
44.5 (±0.2)
40.1 (±0.1)
47.1 (±0.2)
47.1 (±0.1)
46.0 (±0.8)

ΔTm (°C)
2.9 (±0.3)
4.4 (±0.8)
5.2 (±0.6)
3.3 (±0.2)
-1.1 (±0.1)
5.9 (±0.2)
5.9 (±0.1)
4.8 (±0.8)
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Melting temperatures of each compound with MaIspE can be found in table 2-7 with normalized
thermal denaturation curves in figure 2-18. The presence of ADP and CMP separately stabilized
the protein 7°C and 10°C, respectively. Furthermore, EcIspE was analyzed in the presence of
each co-factor and substrate derivative for thermostability. Table 2-8 and figure 2-19 show how
each compound other than adenosine positively impact thermostability of EcIspE.

Figure 2-18. DSF thermal denaturation curves of MaIspE in the presence of substrate and cofactor derivatives.

Table 2-7. Tm of of MaIspE in the presence of substrate and co-factor derivatives.
Compound
No Compound
AMP-PNP
ATP
ADP
AMP
Adenosine
CDP
CMP
Cytidine

Tm (°C)n=2
39.1 (±0.4)
41.2 (±0.7)
43.3 (±0.2)
46.4 (±0.3)
42.5 (±0.3)
39.5 (±0.0)
45.1 (±0.2)
49.1 (±0.1)
43.9 (±0.1)

ΔTm (°C)
2.1 (±0.8)
4.2 (±0.4)
7.3 (±0.5)
3.4 (±0.5)
0.4 (±0.4)
6.0 (±0.4)
10.0 (±0.4)
4.8 (±0.4)
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Figure 2-19. DSF thermal denaturation curves of EcIspE in the presence of substrate and cofactor derivatives.

Table 2-8. Tm of EcIspE in the presence of substrate and co-factor derivatives.
Compound
No Compound
AMP-PNP
ATP
ADP
AMP
Adenosine
CDP
CMP
Cytidine

Tm (°C)(n=1)
52.1
53.5
54.1
55.6
54.2
51.7
55.1
55.5
55.0

ΔTm (°C)
1.4
2.0
3.5
2.1
-0.4
3.0
3.4
2.9

Discussion

Structure/energetic relationships for substrate interactions within IspE’s active site
provide helpful information for inhibitor design. The ability to uncover reliable relationships
relies on a robust understanding of IspE’s physical characteristics. For instance, the presence of
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organic solvents and environmental factors such as temperature and pH can significantly
influence enzyme stability. The stability of the three species used in this study, EcIspE, BtIpsE,
and MaIspE, was rigorously evaluated across pH and ionic strength conditions, as well as the
presence and absence of MgCl2 and DTT. Overall, the three species of IspE displayed highest
stability in reducing conditions at higher ionic strength in the presence of Mg2+ ions. MaIspE was
most sensitive to small variations in pH as indicated by CD and DSF results. For example, CD
experiments examining thermal unfolding at pH 7.0 (50 mM HEPES, 150 mM NaCl, 5 mM
MgCl2, and 1 mM DTT) did not appear to show complete global unfolding, rather two smaller
conformational transitions occurred. On the other hand, the thermal melt at pH 6.0 (50 mM
MES, 150 mM NaCl, 5 mM MgCl2, and 1 mM DTT) displayed a Tm of ~50°C, with complete
global unfolding. While the CD analysis was not performed on EcIspE and BtIspE, DSF
experiments explored IspE stability over a wider pH range. EcIspE was most stable in a
phosphate buffer around physiological pH while BtIspE’s thermostability was greatest in a
citrate pH 6.5 buffer.
The substitution of a serine codon in place of a stop codon successfully expressed pure
EcIspE at a high yield. The elution profile of EcIspE from size exclusion chromatography
resulted in peaks at the exclusion limit, ~66 kDa, and at ~33 kDa. Characterization by SDSPAGE suggested the eluted peak at the exclusion limit as well as at ~66 kDa was in fact EcIspE.
This data correlates with published literature stating that EcIspE dimerizes to some degree.41
Nevertheless, further investigation is needed to identify if EcIspE dimerization is biologically
relevant to the function of the enzyme. On the other hand, MaIspE and BtIspE were produced
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with a high yield and stored as lyophilized product. Size exclusion chromatography confirmed
both species were mostly monomeric in solution. Any evidence of dimerization through SEC and
SDS-PAGE was unclear and would require further evaluation of eluted fractions. With that, all
testing was done using monomeric protein as the true nature of this dimerization was unknown.
Isothermal titration calorimetry experiments with substrate and co-factor derivatives
correlated well with thermal denaturation data obtained from DSF. Of the three species, BtIspE
and MaIspE were evaluated most extensively. Both possessed KD values ranging between 39-150
µM for all co-factor derivatives containing phosphate groups. In turn, the loss of those phosphate
groups heavily impacted binding. For example, no interaction was observed with adenosine and
either BtIspE or MaIspE. Contradictorily, the loss of one phosphate group (e.g., ATP to ADP)
displayed a slight improvement in binding (2-fold), which was observed within both species,
BtIspE and MaIspE. These results suggest the phosphate-binding loop plays an important role in
ATP binding (figure 2-21) and that presence of the charged γ-phosphate group introduces a
penalty towards binding due to its proximity to the hydrophobic region of the active site. The
DSF data obtained for all three species conclusively showed no impact in thermal stability from
adenosine (figure 2-20). On the other hand, all ATP derivatives containing phosphate groups
positively shifted Tm. Furthermore, the CDP-ME derivatives that were tested, showed that the
loss of phosphate groups was not as detrimental to binding within BtIspE. ITC data examining
the binding of CDP, CMP, and cytidine displayed KD values between 50-288 µM. When
evaluating thermostability of these derivatives, it was shown within all species that each
compound positively influenced Tm. This suggests each was binding to IspE. When comparing
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DSF results of CDP-ME substrate derivatives between the three IspE species, MaIspE displayed
the largest shifts in Tm for all compound (figure 2-20).
10
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Figure 2-20. Changes in melting temperature of IspE with substrate and co-factor derivatives.

The best results were obtained for CMP displaying a 10°C positive shift. The
combination of cytidine with at least one phosphate groups suggests this region plays an
important role in substrate binding. As seen in figure 2-22, the α-phosphate on CMP accepts a
strong hydrogen bond from the hydroxyl and main chain carbonyl of SER147. These residues are
implicated as having significant contributions to substrate or co-factor binding. They can serve as
a target for future inhibitor design.
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Figures 2-21. Important binding regions of EcIspE to AMP-PNP. Residues in EcIspE that bind
to the β-phosphate and γ-phosphate on AMP-PNP are highlighted in green.39

Figures 2-22. Important binding interactions in MaIspE to CMP. Residues in MaIspE that bind
to phosphate group in CMP are highlighted in green.42

Chapter 3

THE ENZYMATIC SYNTHESIS OF ISPE SUBSTRATE 4-DIPHOSPHOCYTIDYL-2CMETHYL-D-ERYTHRITOL

Investigation of IspE activity and potential inhibition requires CDP-ME, the IspE
substrate. CDP-ME was synthesized using enzymes found in both glycolysis and in the nonmevalonate pathway. Isotopically labeled 13C-glucose was used to follow eight consecutive
reactions by NMR. In addition, the resulting labeled substrate could be used to confirm the
presence of functional IspE by following conversion of CDP-ME to CDP-MEP by NMR. CDPME has been synthesized using both enzyme-based and traditional organic synthesis approaches.
In 1998 and 1999, Blagg et al. and Taylor et al. reported a hybrid procedure that yielded DOXP
that utilized both enzymatic conversion and small molecule synthesis.67,68 In the next two years,
numerous reports used both methods to form various non-mevalonate pathway intermediates.69–
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These methods required a large number of steps. In 2006, an efficient process yielding

optically pure MEP and 2,4-cyclodiphosphate was published. In general, D-arabitol was
converted to product using a variety of protecting groups.74,75 Similarly, Lagisetti et al. published
a method utilizing alkyl Grignard reagents and hydride nucleophiles that reacted with dioxanone
to produce both MEP and 2,4-cyclodiphosphate.76 These publications focused on other
intermediates of the non-mevalonate pathway, so an enzymatic route published by Illarionova et
al. was referenced and followed in this study to make CDP-ME with only minor modifications.31
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It laid out the substrate synthesis and high-throughput screening methods for IspC,D,E and F
used by their group. Commercial sources sold CDP-ME at low volume and high cost which did
not suffice to execute various procedures in this study. In turn an in-house method was
established in attempts to provide that supply. All in all, this procedure proved to be an effective
way to produce CDP-ME but future work will require optimization to extract pure substrate from
the crude mixture.
Methods

Reagents for CDP-ME Synthesis

The reagents required for this procedure were purchased from Sigma Aldrich or obtained
from SSGCID. Products purchased from Sigma Aldrich were hexokinase, glucose 6-phosphate
isomerase, fructose 6-phosphate kinase, triose phosphate isomerase, fructose 1,6-biphosphate
aldolase, pyruvate kinase, thiamine diphosphate, potassium phosphoenol pyruvate, ATP, [U13

C6]-glucose, glucose dehydrogenase, inorganic pyrophosphatase, CTP, unlabeled glucose, and

NADP+. The activity of each enzyme was defined in the certificate of analysis. In turn, the nonmevalonate pathway enzymes, DXS, IspC, and IspD were obtained from SSGCID. DXS
(Butha.17230.b.A1 GE32773) was purified in-house using an expression construct while IspC
(AnphA.01136.a.A1.PW26996) and IspD (AnphA.01136.a.A1.PW26996) came already purified.

66

Expression and Purification of 1-Deoxy-D-Xylulose-5-Phosphate Synthase (DXS)32,62,77,78

The conversion of glyceraldehyde-3-phosphate and pyruvate to 1-deoxy-D-xylulose-5phosphate (DOXP) was catalyzed by the enzyme DXS that was purified in-house. The vector
map and expected protein sequence of the expression clone that was obtained from SSGCID can
be seen in figure 3-1. See appendix C for DNA and protein sequence overlay for DXS. A similar
expression procedure used for BtIspE and MaIspE found in chapter 2 was followed for DXS.
Specifically, the vector that incorporated the gene for this enzyme was engineered with a
resistance for ampicillin. Another difference was that the final 1L culture was supplemented with
200 µM TPP. During purification, each frozen pellet was resuspended in lysis buffer (20 mM
HEPES pH 7.0, 300 mM NaCl, 30 mM Imidazole, 21 mM MgCl2, and 1 mM DTT), sonicated,
and centrifuged at 16,000 rpm for 20 min. at 4°C. Initially, HisTrap HP nickel affinity IMAC
column (GE Healthcare Life Sciences) was used on a ӒKTAprime Plus (GE Healthcare Life
Sciences) fast protein liquid chromatography (FPLC) system. The lysate was loaded onto the
column with loading buffer (20 mM HEPES pH 7.0, 300 mM NaCl, 30 mM Imidazole, 1 mM
DTT) and eluted by step elution using the same buffer with 500 mM imidazole. The final
purification step included size exclusion chromatography. Prior to running, the HiPrepTM 26/60
SephacrylTM S-200 HR size exclusion column was equilibrated with 2 column volumes of size
exclusion buffer (20 mM TRIS pH 7.2 150 mM NaCl, 1 mM DTT). SDS-PAGE was run to
assess the purification protocol. The concentration of protein was determined at 280 nm using
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the extinction coefficient 34,840 M-1cm-1 (Molecular Weight: 70,576 Da). Purity was
determined using public domain ImageJ1.51j8 NIH software. Purified protein was stored in size
exclusion buffer with 20% glycerol. Prior to -80°C storage, aliquots were flash frozen for single
use.
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DXS: MAHHHHHHMG TLEAQTQGPG SMYDLLKTID DPADLRRLDR RQLQPLADEL RAFVLDSVSK TGGHLSSNLG TVELTIALHY VFNTPDDRIV WDVGHQTYPH
KILTGRRDGM KTLRQFDGIS GFPRRSESEY DTFGTAHSST SISAALGMAI GSKLNGDDRF SIAVIGDGAM TAGMAFEAMN NAGVSEDAKL LVILNDNDMS ISPPVGALNR
HLARLMSGRF YAAARAGVER VLSVAPPVLE LARKLEEHAK GMVVPATLFE EFGFNYIGPI DGHDLDSLIP TLQNIKELRG PQFLHVVTKK GQGYKLAEAD
PVLYHGPGKF NPAEGIKPSA TPAKKTYTQV FGEWLCDAAE LDARVVGITP AMREGSGMVE FEKRFPERYY DVGIAEQHAV TFAGGLATEG LKPVVAIYST
FLQRAYDQLI HDVALQNLPV VFAIDRAGLV GADGATHAGA YDLAFLRCIP NMTVMAASDE NECRQMLHTA LQQPNPTAVR YPRGAGTGVA TVKAFTEIPL
GKGEVRRRTS QPDGKRVAIL AFGTMVAPSL AAADALDATV ANMRFVKPID AELVRELAQT HDYLVTVEEG CVMGGAGSAC VEAMMEGGAV RPVLQLGLPD
RFVDHGDPAK LLAMCGLDGD GIAKSIRERF LNHAANVASP AKRVA

DXS:ATGGCTCATCACCATCACCATCATATGGGTACCCTGGAAGCTCAGACCCAGGGTCCTGGTTCGATGTACGACTTGCTGAAAACCATCGACGACCCGGCGGACCT
GCGCCGTCTCGATCGTCGCCAACTGCAGCCGCTCGCCGACGAGCTGCGCGCGTTCGTTCTCGACAGCGTGTCGAAGACGGGCGGCCATTTGTCGTCCAATCTCGGCAC
GGTCGAGCTGACGATCGCGCTGCATTACGTGTTCAACACGCCGGACGACCGGATCGTGTGGGACGTCGGTCACCAGACCTATCCGCACAAGATCCTGACGGGCCGCC
GCGACGGGATGAAGACGCTGCGCCAGTTCGACGGCATCTCGGGCTTTCCGCGCCGCTCGGAATCCGAATACGACACGTTCGGCACCGCGCACTCGAGCACGTCGATC
TCGGCTGCGCTCGGGATGGCGATCGGCAGCAAGCTGAACGGCGACGACCGCTTCTCGATCGCGGTGATCGGCGACGGCGCGATGACGGCCGGCATGGCGTTCGAGG
CGATGAACAACGCGGGCGTGTCCGAGGACGCGAAGCTCCTCGTGATCCTGAACGACAACGACATGTCGATCTCGCCGCCCGTCGGCGCGCTGAACCGCCATCTCGCG
CGCCTGATGTCGGGCCGCTTCTACGCGGCCGCGCGCGCGGGCGTCGAACGCGTGCTGAGCGTCGCGCCGCCCGTGCTCGAGCTCGCGCGCAAGCTCGAGGAGCATGC
GAAGGGCATGGTGGTGCCCGCGACGCTCTTCGAGGAATTCGGCTTCAACTACATCGGGCCGATCGACGGCCACGATCTCGATTCGCTGATCCCGACGCTGCAGAACA
TCAAGGAACTGCGCGGCCCGCAGTTCCTGCACGTCGTGACGAAGAAGGGACAGGGCTACAAGCTCGCTGAGGCCGATCCGGTGCTCTATCACGGGCCCGGCAAGTTC
AACCCGGCGGAAGGCATCAAGCCGTCCGCGACGCCGGCGAAGAAGACCTACACGCAGGTATTCGGCGAATGGCTGTGCGACGCGGCGGAGCTCGATGCGCGCGTGG
TCGGCATCACGCCCGCGATGCGCGAAGGCTCGGGCATGGTCGAGTTCGAGAAGCGCTTCCCGGAGCGCTACTACGACGTCGGCATTGCCGAGCAGCACGCGGTGAC
GTTCGCGGGCGGCCTCGCGACGGAAGGGCTCAAGCCCGTCGTCGCGATCTACTCGACTTTCCTGCAGCGCGCCTATGATCAGCTGATTCACGACGTCGCGCTGCAGA
ACCTGCCCGTCGTGTTCGCGATCGATCGCGCGGGCCTCGTCGGCGCGGACGGCGCGACGCATGCGGGCGCATACGATCTCGCATTCCTGCGCTGCATCCCGAACATG
ACGGTGATGGCCGCGTCGGACGAGAACGAGTGTCGCCAGATGCTGCACACCGCGCTGCAGCAGCCGAACCCGACCGCGGTCCGTTATCCGCGCGGCGCAGGCACGG
GCGTTGCGACCGTCAAGGCGTTCACCGAGATTCCGCTCGGCAAGGGCGAAGTGCGCCGTCGCACGTCGCAGCCGGACGGCAAGCGCGTCGCGATTCTCGCGTTCGGC
ACGATGGTCGCGCCGTCGCTTGCGGCCGCCGACGCGCTCGACGCGACCGTGGCGAACATGCGTTTCGTGAAGCCGATCGACGCCGAGCTCGTTCGAGAGCTCGCGCA
GACGCACGACTACCTCGTCACCGTCGAGGAAGGCTGCGTGATGGGCGGCGCGGGCTCCGCGTGCGTCGAGGCGATGATGGAAGGCGGCGCGGTCCGTCCGGTGCTG
CAGCTCGGCCTGCCGGACCGCTTCGTCGATCACGGCGATCCGGCGAAGCTGCTTGCGATGTGCGGTCTCGACGGCGATGGCATCGCGAAATCGATTCGCGAGCGCTT
CCTGAACCACGCGGCGAACGTCGCGAGTCCGGCGAAGCGCGTCGCATAA

Figure 3-1. DXS Vector Map and Expected Protein and DNA Sequences.
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Enzymatic Synthesis of CDP-ME

The enzymatic synthesis of CDP-ME was done in three steps. Initially, the glycolytic
preparatory phase was executed to produce glyceraldehyde 3-phosphate followed by the
immediate conversion to DOXP. Again, uniformly 13C-labeled glucose was used to follow the
reaction by NMR. To begin, 4.9 mmol [U-13C6]-glucose, 0.18 mmol ATP, 1.5 mmol DTT, 0.65
mmol TPP, and 10.6 mmol PEP were added to a 60 mL buffered solution containing 150 mM
TRIS-HCl pH 8.0 and 10 mM MgCl2. The subsequent change in pH was then adjusted back using
2 M NaOH. Once the pH stabilized, 250 U Hexokinase, 114 U glucose 6-phosphate isomerase,
10 U fructose 6-phosphate kinase, 124 U triose phosphate isomerase, 12 U fructose 1,6biphosphate aldolase, 118 U pyruvate kinase, and 3 mg DXS were dissolved in 4 mL above
buffer and added to the initial mixture. The final volume was 64 mL. The mixture was incubated
at 37°C. Aliquots of 100 µL were retrieved and diluted with D2O to 700 µL. These were further
analyzed by 13C-NMR spectroscopy using a Bruker 300 MHz spectrophotometer. After
confirmation of product formation, the reaction was filtered using Amicon® Ultra-15 centrifugal
filters 3000 NMWL. The total run time was 3 hours. See figure 3-2 for the pathway.
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Figure 3-2. Formation of DOXP from glucose. Uniformly 13C-labeled glucose was used to
follow the reaction progress. The carbon atoms designated by a red dot show which were
labeled.

The second step produced 2C-methyl-D-erythritol 4-phosphate (MEP). The filtered
solution above was used as is without purification. To the filtered 64 mL of DOXP solution, 11
mmol of unlabeled glucose, 300 mmol NADP+, 30 U glucose dehydrogenase, and 4.8 mg IspC
were added and incubated overnight at room temperature. The glucose dehydrogenase was used
to replenish NADPH. The solution was consistently kept at pH 8.0. Product formation was once
again monitored by 13C-NMR spectroscopy using the above procedure and was confirmed to be
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complete after 15 hours. This mixture was again filtered and further lyophilized using a
Labconco FreeZone 4.5 unit. See figure 3-3 for the reaction scheme.

Figure 3-3. IspC catalyzed reaction for MEP formation. IspC catalyzes the rearrangement of
DOXP to MEP. The carbon atoms designated by a red dot show which were labeled.

The third and final step involved the production of CDP-ME. The lyophilized solid was
dissolved in 30 mL buffer (150 mM TRIS-HCl pH 8.0, 10 mM MgCl2). Then 1.5 mmol DTT,
4.3 mmol CTP, 1.2 mg IspD, and 20 U of inorganic pyrophosphatase were added and incubated
at 37°C. The inorganic pyrophosphatase was used to break down pyrophosphate and drive the
reaction forward. As before, the pH was consistently monitored and adjusted to 8.0 and 13CNMR spectroscopy was used to analyze the product. Once complete, the solution was filtered
and lyophilized using the above procedure. This step was also complete after 3 hours. See figure
3-4 For the reaction scheme. The crude reaction mixture was stored at -80°C.
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Figure 3-4. IspD catalyzed reaction for CDP-ME formation. IspD catalyzes the formation of
CDP-ME using MEP and CTP as substrates. The carbon atoms designated by a red dot show
which were labeled.

Results

Expression and Purification of 1-Deoxy-D-Xylulose-5-Phosphate Synthase (DXS)

The expression and purification procedure obtained active and relatively pure DXS
enzyme. Expression of the protein resulted in an on average 9g cell pellet from a 1L culture. The
step elution used on the nickel/HIS tag affinity column was monitored by UV (280 nm
absorbance) and all fractions associated to that peak were collected and concentrated to 5 mL.
The presence of protein was verified by UV using a NanoDrop 2000c spectrophotometer
(Thermo Scientific). Subsequent purification using size exclusion chromatography eluted a peak
associated with DXS was collected, concentrated and stored in the freezer. See figure 3-5 and 36 for chromatograms pertaining to the first and second step. By the end, purification of a cell
pellet obtained from a 1 L culture produced 16 mg of purified protein. See figure 3-7 for the
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resulting SDS-page gel. Fractions eluted in void volume were sampled in wells 2 and 3 while
fractions corresponding to the molecular weight of DXS were loaded into wells 4 thru 8.

Figure 3-5. Chromatogram of HisTrap affinity column purification of DXS.

Figure 3-6. Chromatograms of purified functional DXS. Size exclusion profile with DXS (black)
and molecular weight standards (red). Standards: Blue Dextran at exclusion limit = 2,000 kDa,
Ovalbumin = 43 kDa, BSA = 67 kDa, and Cytochrome C = 12 kDa.
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Figure 3-7. SDS-PAGE of size exclusion fractions of DXS. Fractions collected at the exclusion
limit (lanes 2-3) and peak at ~70 kDa (lanes 4-8) were evaluated.

Enzymatic Synthesis of CDP-ME

The formation of intermediates and CDP-ME was confirmed by 13C-NMR. The initial
spectra that was taken indicated the presence of [U-13C6]-glucose. D-glucose is present in
solution in either its α or β form. The difference between the two structures is found at the
anomeric carbon. In β-D-glucose, the hydroxyl group is in the same plane as the methoxy group
found in the C-6 position while the same group in α-D-glucose is not in plane79. The presence of
doublet peaks at 92.2 and 96.0 ppm correspond to the anomeric carbon of each isomer. The
group of peaks found between 69.1 and 76.6 ppm correspond each triplet peak of carbons C2-C5.
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The differences between the two isomers of glucose are relatively minor between these carbons.
Lastly, the carbon for each isomer at position C6 is present upfield between 60.6 and 61.1 ppm.
Again, these differences are relatively minor. See figure 3-8 for the NMR spectra obtained at the
beginning and end of step 1. DOXP was confirmed through the presence of a triplet signal at
70.9 ppm and two doublet peaks at 64.4 and 77.2 ppm. The two peaks found at about 60.7 and
60.2 ppm in each spectrum correlate to the TRIS buffer used in the reaction.

Figure 3-8: 13C-NMR Spectra of glucose to DOXP. 13C-NMR Spectra of starting reaction
containing glucose (top) and spectra of sample taken 3 hours after reaction was initiated by
glycolysis enzymes and DXS (bottom).
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Table 3-1: NMR parameters of glucose and DOXP
13C-NMR

Data for Reactants and Products
Chemical Shift (ppm)
Coupling constant (Hz) JCC
13
[U- C6]-Glucose (1)
92.2
43.7
71.0-72.1
38.8, 42.5
75.5-76.6
36.4
69.1-70.2
39.8, 38.8
71.0-72.1
41.4, 42.4
60.6-61.0
41.4
96.0
45.6
74.3-74.8
41.7
75.5-76.6
41.9
69.1-70.2
39.8, 38.8
75.5-76.6
42.3
60.9-61.1
43.0
13
[3,4,5- C3]-1-deoxy-D-xylulose-5-phosphate (2)
77.2
39.4
70.9
41.7, 42.6
64.4
43.3

Position of Carbon
α-1
α-2
α-3
α-4
α-5
α-6
β-1
β-2
β-3
β-4
β-5
β-6
3
4
5

The formation of MEP was seen after the conclusion of the second step in the reaction.
The singlet found at 66.6 ppm corresponds to the carbon at position C1 while no significant shift
was seen in the final carbon at approximately 64.0 ppm (figure 3-9). Lastly, the environment
around C3 of MEP changed and shifted to 74.0 ppm (figure 3-9).
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Figure 3-9: 13C-NMR Spectra and parameters of DOXP to MEP. 13C-NMR spectra of reaction
containing DOXP (top) and spectra of sample taken 15 hours after reaction was initiated by IspC
(bottom).

Table 3-2: NMR parameters of DOXP and MEP
13C-NMR

Data for Reactants and Products
Position of Carbon
Chemical Shift (ppm)
Coupling constant (Hz) JCC
[3,4,5-13C3]1-deoxy-D-xylulose-5-phosphate (2)
77.2
39.4
3
70.9
41.7, 42.6
4
64.4
43.3
5
[1,3,4-13C3]2C-methyl-D-erythritol 4-phosphate (3)
66.6
1
74.0
42.0
3
64.8
42.3
4
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The third and final step was confirmed complete after the formation of CDP-ME (4). The
only major shift in the 13C-NMR spectra was seen from the carbon at the C4 position. It shifted
from 64.8 to 67.1 ppm. See figure 3-10 for spectra and parameters corresponding to each peak.

Figure 3-10: 13C-NMR Spectra and parameters of MEP to CDP-ME. 13C-NMR spectra of
reaction containing MEP (top) and spectra of sample taken after another 3 hours after reaction
was initiated by IspD (bottom).
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Table 3-3: NMR parameters of MEP and CDP-ME
13C-NMR

Data for Reactants and Products
Position of Carbon
Chemical Shift (ppm)
Coupling constant (Hz) JCC
13
[1,3,4- C3]2C-methyl-D-erythritol 4-phosphate (3)
66.6
1
74.0
42.0
3
64.8
42.3
4
13
[1,3,4- C3]4-diphosphocytidyl-2C-methyl-D-erythritol (4)
66.5
1
73.5
41.8
3
67.1
42.8
4
Discussion

The enzymatic synthesis of CDP-ME was executed successfully following the formation
of the DXS intermediate, DOXP and the IspC intermediate, MEP. Over the course of optimizing
the reaction, enzymes purchased from the commercial source lost desired activity when stored
for longer periods of time. This suggests fresh reagents should be purchased for new trials.
Repeat freeze-thaw cycles most likely contributed to this loss in activity. Initial attempt of the
enzymatic synthesis suggested the first step of the reaction did not produce DOXP nor the two 3carbon units of glyceraldehyde 3-phosphate (figure 3-11).
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Figure 3-11. Conversion of glucose to DOXP was not observed through NMR. The 13C-NMR
spectrum of the initial mixture prior to any enzyme addition (top) was characteristic of uniformly
labeled glucose. The 13C-NMR spectrum taken after step 1 (bottom) showed no DOXP
formation.

As a result, new hexokinase and aldolase enzymes were purchased. In addition, the DXS
purification protocol was modified to include the addition of TPP. Furthermore, the purification
procedure implemented for DXS resulted in >90% purity as characterized by the SDS-page gel.
The protein yield and purity were satisfactory for what was needed the reaction, so no further
optimization was done. Conclusively, these modifications worked well as the 13C-NMR spectra
confirmed the formation of each intermediate and final product.
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The conversion of glucose to DOXP was seen from product formation in the 13C-NMR
spectra (fig. 3-9). The addition of a two-carbon unit to glyceraldehyde 3-phosphate came from
pyruvate. It is worth noting that pyruvate came from excess addition of phosphoenolpyruvate. It
was regenerated from PEP by pyruvate kinase and ADP. Furthermore, the ATP produced as a biproduct further replenished any additional substrate that was needed throughout reactions in step
1. Since 13C-PEP was not used, C1 and C2 on DOXP was not seen in the NMR spectra. The
expected 1% isotope population normally detected by 13C-NMR was overwhelmed by the
carbons purposefully labeled in this study. Due to this fact, C3 was expressed as a doublet rather
than a triplet peak. Furthermore, the rearrangement and reduction of DOXP to MEP was seen
from the formation of C1 as a singlet at 66.6ppm and the shift in C3 on MEP to 74.0 ppm (fig, 310). Lastly, no structural differences were present between MEP and the methylerythritol tail on
CDP-ME. Product formation was confirmed through a deshielding effect that an additional
phosphate group had on C4. This shift was seen from the doublet peak that went from 64.8 to
67.1 ppm (fig. 3-10). These values were compared and confirmed to previously published
results.31,80 The enzymes used in the synthesis were easily extracted by filtration but residual
ATP, ADP, PEP, pyruvate, NADPH, NADP+, CMP and glucose were still present. These
compounds have the potential to interfere in future testing so further purification was needed. On
the other hand, active IspE can be validated using this crude mixture as the isotopically labeled
carbons will only show in the spectra. Furthermore, this method produces intermediates in the
non-mevalonate pathway that can be used to study substrate conversion for their respective
enzymes.

Chapter 4

ASSAY DEVELOPMENT TO EVALUATE THE ABILITY OF 4-QUINAZOLINONE
COMPOUNDS TO INHIBIT ISPE ACTIVITY

Evaluating inhibition of IspE requires an assay to detect changes in substrate turnover
rate in the presence of small molecule inhibitors. An assay can evolve into a high throughput
screen to test thousands of compounds against the target enzyme. The assay should be able to be
performed a plate based format such as 96 or 384 well plates. This high-volume screening is
highly reliant on reproducibility. Two types of general assays are implemented for these sorts of
assays. A continuous assay measures activity over time while an end-point assay quenches the
reaction and reads at a single time-point.81 An example of an end-point high throughput
screening procedure first adds enzyme solution to a microtiter plate holding compound followed
by an incubation period. Substrate initiates the reaction followed by another incubation period
prior to detecting any signal changes.82 This study will depend on the development of a
luciferase-based coupled assay. Specifically, the Kinase-Glo® Plus luminescence kit from
Promega was used (figure 4-1). After incubation, this end-point assay quenches the reaction and
any left-over ATP is consumed by luciferase and oxidized to oxyluciferin. This reaction
produces one photon of light per turnover of ATP in solution.83
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Figure 4-1. Kinase-Glo reaction detects ATP concentration. The phosphorylation of CDP-MEP
by CDP-ME can be monitored through consumption of left-over ATP by beetle luciferin.

The quality of an enzyme is important in high throughput screening of
compounds. As described in chapter 2, the purity and stability of EcIspE, BtIspE, and MaIspE
was evaluated. High purity of enzyme and inhibitors are needed to avoid false detection of
activity.84 Other factors can be found and evaluated through previously published assay
guideline. Verification of the published protocol can be done through purchasing reference
compounds reported in those studies. To detect rate changes with potential inhibitors, a thorough
understanding of the enzymes kinetic and thermodynamic parameters should be understood.
Results between different lots of enzyme can confirm lot-to-lot consistency. If activity is lost,
sensitivity for inhibitor detection is compromised.85 Knowledge of the Km constant verifies
correct concentration of substrate is used. For example, if uncompetitive or noncompetitive
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inhibition is targeted, the concentration of substrate should be ten times higher than the Km. On
the other hand, if competitive inhibition is studied, the concentration of substrate should be at or
below Km of substrate.24 Detecting the rate of a reaction requires the incubation period of an
assay to be within linear range. If the reaction is too fast, detecting potential inhibitors can be
missed and the sensitivity of the assay may be compromised.85 As some inhibitors bind slowly,
immediate substrate conversion fails to detect these compounds. The concentration of enzyme
with substrate should produce the largest dynamic range within the linear progression of the
reaction. This is determined empirically through varying IspE kinase concentrations with a
consistent amount of substrate.
Control reactions within an assay are validated through calculated statistical parameters
that evaluate its quality along with the reproducibility of reference compounds. These parameters
include the signal-noise ratio (S/N), coefficient of variation (CV) across wells and the Z’ factor.
The signal to noise ratio should be at least 2 while the coefficient of variation between replicate
trials should be no more than 10%. The Z’ factor addresses the dynamic range between positive
and negative controls and combines principles of S/N and coefficient of variation. The result of
this calculation should be between 0.5-1.0 for an acceptable assay (figure 4-2).
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Figure 4-2. The Z-factor scale. A model of optimal separation (left) and Z’ factor ranges (right)
categorize the quality of an assay using a simple calculation. Adopted from Sittamplalam24 and
Zhang86.

Furthermore, reference compounds should inhibit IspE with similar potency and be
addressed for interference with the detection method. The compounds chosen as controls for this
study were luciferase inhibitor 1 and resveratrol for the luciferase inhibition assay and
compounds 3-6 in figure 4-2 for the IspE inhibition assay. HGN-0940 was initially evaluated by
Dr. Prabagaran Narayanasamy (University of Nebraska Medical Center) and HGN-0333 was
previously found to inhibit EcIspE and BtIspE from preceding work on this project. Using these
compounds and following these validation guidelines can ensure an assay is developed
successfully to identify hit compounds.81
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Luciferase Inhibitor 1

HGN-0333

Resveratrol

HGN-0779

HGN-0940

HGN-0813

Figure 4-3. Reference compounds used for assay development. Compound 1 and 2 were
reported to previously inhibit firefly luciferase (IC50: 20 µM and 12 µM) while compounds 3-6
were found to inhibit MtIspE, BtIspE, or EcIspE at various concentrations.49,51,87,88

Inconsistent results between plates can come from various sources. The Assay Guidance
manual developed by Eli Lilly and Company define which factors contribute the most to these
issues.81 Included sub-sections discuss reagent stability, validation protocols for plate uniformity
and signal variability assessments, plate acceptance criteria, and inherent drift or edge effects.
They address that all reagents used must be evaluated for stability in storage and in solution.
This is especially important as reagents must remain stable throughout the time the assay is
performed. Furthermore, exposure of enzymes to DMSO must be evaluated for activity loss as
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variable solvent concentrations can produce inconsistent results. DMSO is frequently used to
facilitate compound solubility in aqueous buffer. Furthermore, plate uniformity and signal
variability evaluations are done to ensure data is reproducible.89–93 Factors such as signal drift
and edge effect can also affect results. Edge effect is a phenomenon observed when signal is
weakened in samples loaded in wells around the edge of the plate. All in all, in combination with
validated statistical parameters, these factors contribute to the quality of a developed assay.
Previously reported inhibitors of IspE, discussed in chapter one, used either the KinaseGlo® Plus luminescence assay from Promega or a pyruvate kinase/lactate dehydrogenasecoupled assay. Notably, an alternative fluorescence-based assay developed by Eoh et al. could be
used in future testing. It monitors signal produced by the dye resorufin.94 The pyruvate
kinase/lactate dehydrogenase-coupled continuous assay monitors depletion of signal at 340 nm
caused by the oxidation of NADH facilitated by LDH (figure 4-3). It initially relies on the
formation of ADP which is further phosphorylated back to ATP by pyruvate kinase.
Phosphoenolpyruvate is used as the phosphorylating agent. Furthermore, the pyruvate formed in
the reaction is used up by LDH to oxidize NADH. In comparison to the Kinase-Glo™ kit, this
continuous assay can more efficiently define the kinetic parameter Km. Previous results reported
that EcIspE has a Km between 150-200 µM for CDP-ME and 20 µM for ATP.40,49
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Figure 4-4. Continuous assay that monitors ADP formation. The pyruvate kinase/lactate
dehydrogenase-coupled assay can detect ATP consumption of IspE by monitoring reduction of
NADH to NAD at 340 nm.

Two groups addressed inhibition of IspE by 4-quinazolinone compounds.51,52 It was
shown by Tidten-luksch et al. that compounds in figure 4-4 exhibited IC50 values at 2.5 µM and
27 µM concentrations. The assay they used was the Kinase-Glo® Plus kit from Promega and was
performed under the following conditions: 90 µM, ATP, 500 µM CDP-ME, 200 nM EcIspE in
100 mM Tris-HCl pH 8.5, 20 mM MgCl2, 2% DMSO, 0.01% (v/v) Triton-X 100. The substrate
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and co-factor concentrations were at ~3×KM and ~0.2×KM, respectively. It is worth noting that
the CDP-ME concentration is above the recommended limit for investigating competitive
inhibition. On the other hand, Persch et al. reported in reference data the results obtained from
that study were not reproducible by their robust assay.52 They hypothesized the auxiliary enzyme
luciferase in the Kinase-Glo luminescence assay was inhibited instead. Therefore, that
contradiction was evaluated in this study.
A

B

Figure 4-5. Published EcIspE inhibitors with 4-quinazolinone sub-structure. A) Compound 1. B)
Compound 2.

Methods

Synthesis and Characterization of 4-quinazolinone compounds95,96

The 4-quinazolinone compounds questioned to inhibit IspE were synthesized in a threestep reaction (figure 4-5). The initial synthesis trial failed to isolated compound 1 at high purity.
The procedure that was implemented resulted in a 23% yield with 82% purity. Notably, a purity
of >95% is recommended when testing compounds as potential inhibitors. An optimized
procedure was accomplished by Dr. Gidget Tay (Rockford University, Illinois). Isolation of
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intermediates and longer run times resulted in obtained compound 1 with a final 58% yield at
greater than 95% purity. A methoxy derivative was also synthesized with a 72% yield with
greater than 95% purity. The new procedure began with dissolving methyl anthranilate (4.37
mmol) in DCM within a round bottom flask followed by the addition of excess TEA and
nicotinoyl chloride (5.21 mmol). This reaction was incubated at room temperature while stirring
for 24 hours. Reaction was quenched with water and extracted with excess DCM. It was further
washed with water and brine solution. The organic layer was extracted and dried over anhydrous
Na2SO4 and concentrated under reduced pressure. This intermediate (compound 5) was purified
over 75% DCM: 25% ethyl acetate column with 96% yield. A mixture of the ester intermediate
(5.85 mmol) and thionyl chloride were refluxed at 70°C for 24 hrs to form compound 7 (figure
4-5). Furthermore, this intermediate was used to synthesize the 4-quinazolinone compounds 1
and 2.
Characterization of synthesized compounds was performed through 1H-NMR, 13C-NMR,
mass spectrometry, and HPLC analysis. All 1H-NMR and 13C-NMR NMR spectra were obtained
using 300 MHz Bruker Avance III spectrometer at room temperature in deuterated chloroform or
DMSO (Cambridge Isotope Laboratories, Inc.). Purity was measured by Agilent HPLC equipped
with an Alltech C18, 5 µm, 150 mm column using the following method: Solvent A (H2O with
0.01% TFA), Solvent B (MeOH); 0-20 min. (10-90% solvent B); 20-25 min. (90-10% solvent
B). Lastly, molecular weight was verified using a Thermo Finnigan LTQ linear ion trap mass
spectrometer with electrospray ionization. Solutions were diluted in MeOH and measured in
positive mode.

91

Figure 4-6. Two synthetic routes for producing 4-quinazolinone compounds. Initial synthesis
route produced compound 1 with 82% purity. The alternate route produced compounds 1 and 2
in high purity from intermediate 7.

Assay Development for Luciferase Inhibition

Coupled inhibition assays run the risk of producing false positives if compounds inhibit
the assay’s auxiliary enzymes.24 The Kinase-Glo Plus kit uses a trademarked Ultra-Glo luciferase
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that is a variant of the enzyme found in the Photuris pennsylvanica firefly.97 There have been
several publications addressing luciferase inhibition of various compounds that inhibited the
enzyme at low micromolar concentrations.87,97–99 These studies were by no means exhaustive, so
a screen was developed to address if 4-quinazolinone compounds inhibited the auxiliary enzyme
luciferase in the Kinase-Glo assay.52 The solution preparations were the same as described
below for IspE inhibition except that CDP-ME was not included.
Statistical parameters and validation techniques used in assay development ensured a
reproducible and robust screen addressed luciferase inhibition. The protocol provided by
Promega defined optimization parameters for using the enzyme in an assay.83 Aliquots of
prepared luciferase in the proprietary buffer were flash frozen and stored in -20°C. The
recommended protocol was followed by using a 1:1 mixture of the detector reagent with the
reaction mixture. Furthermore, the concentration of ATP (40 µM) was held constant between this
assay and the IspE inhibition assay. To ensure stability of ATP, it was prepared fresh each time.
Concentration of ATP was further determined at 259 nm with the extinction coefficient 15.4
mM-1cm-1. Reference compounds resveratrol and luciferase inhibitor 1 were evaluated for each
assay trial controls. Furthermore, the negative control (no inhibition) substituting DMSO for the
compound while the positive control (full inhibition) intentionally left out ATP to simulate full
inhibition of the luciferase enzyme. In turn, DMSO concentrations were consistent in all
samples. Lastly, to avoid potential edge effects, samples were only tested within inner wells and
drift was analyzed by measuring luminescence at 30, 45, and 60 minutes to confirm that 45
minutes was an optimal incubation period for a stabilized signal. Statistical assay validation
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parameters (S/N, CV, Z’factor) were calculated for each trial and OriginPro 8 Boltzmann fit was
used to determine IC50 of all reactions.
Assay Development for IspE Inhibition

The Kinase-Glo® PLUS Luminescence kit from Promega was optimized to primarily
detect inhibition of BtIspE.49 As mentioned previously, luciferase oxidizes luciferin using leftover ATP to emit photons of light. Hence, luminescence is used as the detection readout of ATP
that remained after the IspE reaction. White polystyrene plates with 384, flat-bottom plates were
chosen to minimize background interference and well-to-well influence. Conditions used were as
followed (in final concentration): 60 mM NaCl, 5 mM MgCl2, 20 mM HEPES pH 8.0, 1 mM
DTT, 5% DMSO (to improve compound solubility), 0.01% w/v BSA, 200 µM CDP-ME, 40 µM
ATP, and a pre-determined amount of IspE all at a final volume of 25 µL. Initially, the buffer
containing 250 mM HEPES pH 8.0, 750 mM NaCl, and 62.5 mM MgCl2 was prepared. It was
further filtered and degassed by vacuum filtration. A stock of 0.5% w/v BSA in ddH2O was
prepared in bulk and aliquoted into 500 µL portions for storage in -80°C freezer. When needed,
one aliquot was equilibrated to room temperature the day of the experiment. Stock solutions of
DTT, ATP, and IspE were prepared fresh and dissolved in either ddH2O or buffer (IspE). The
substrate, CDP-ME (Echelon Biosciences #I-M052) was diluted in acidic buffer between pH 5-6
and dispensed into 100 µL aliquots.100 These were further flash frozen and stored at -80°C.
Aliquots were equilibrated to room temperature once needed.
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To begin, a master solution was prepared containing reagents that were present in all
wells. See table 4-1 for stock and final concentrations. A concentration test was executed to
determine an optimal amount of kinase to be used in the subsequent inhibition assay. The master
solutions included everything except DMSO and BtIspE for the concentration test and everything
except compound and substrate for the inhibition assay. The DMSO/compound was first
aliquoted, and the plate was then centrifuged at max speed (2,250 × g) for 1 minutes. The master
mixture was then added and again spun down. Different concentrations of enzyme with 200 µM
CDP-ME were tested for optimal concentration and incubated for 45 minutes while shaking at
room temperature. The plate was protected from light. In turn, the inhibition assay left the
enzyme incubating with compound for 15 minutes prior to substrate addition. CDP-ME was
added and the plate was centrifugated once more. This plate was then exposed to the same
incubation period as for the concentration test. After the desired incubation period, 25 µL of the
detector reagent was added and spun down for 1 minutes. A Biotek Synergy 2 plate reader was
used to detect luminescence signal at 25°C with a pre-incubation period of 15 minutes at the
same temperature. Lastly, statistical parameters (S/N, CV, and Z’factor), edge-effect, and signal
drift was analyzed the same way as described for the luciferase inhibition assessment.
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Table 4-1. Kinase-Glo Reagent concentrations.
Reagent
HEPES pH 8.0
NaCl
MgCl2
DTT
BSA
CDP-ME
ATP
IspE

[Stock]
250 mM
750 mM
62.5 mM
12.5 mM
0.5% w/v
2.5 mM
500 µM
Variable

[Final]
20 mM
60 mM
5mM
1mM
0.01% w/v
200 µM
40 µM
Variable

Verification of Inhibitor Binding to IspE

Assay development can be a tedious process, so alternative methods were implemented to
verify reference compound binding. Isothermal titration calorimetry and differential scanning
fluorimetry were executed with EcIspE and BtIspE to address binding of the potential inhibitors
mentioned above. The procedures for both ITC and DSF were the same as described in chapter 2.
Buffer conditions used were as follows: 50 mM HEPES pH 7.0, 150 mM NaCl, 5 mM MgCl2,
and 1 mM TCEP (ITC)/ 1mM DTT (DSF). A concentration of 250 µM compound was used for
each analysis.
Results

Synthesis and Characterization of 4-Quinazolinone Compounds

In order to characterize the interactions of the 4-quinazolinone compounds, pure material
was needed. Initial attempts to synthesize compound 1 indicated that the desired compound was
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synthesized, however the purity was about 82% (figure 4-5). Attempts to further purify the
product were unsuccessful. The optimized synthetic route that produced highly pure 4quinazolinones was completed by Dr. Gidget Tay and I fully characterized the products and
intermediates. Modifications to the synthesis were made to eliminate contamination from starting
materials. Compound 7 was used as an intermediate to further synthesize the 4-quinazolinone
compounds. Compound 7 was not isolated, so the purity obtained through HPLC analysis was
inconclusive as multiple peaks eluted within the run time. Without a standard, assigning the
proper peak to the product by retention time was difficult. The final products obtained were
rigorously characterized and results were reported below.
Synthetic Procedures and Characterization Results
2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one:

Methyl 2-(nicotinamido)benzoate (2.6 g, 10.1 mmol) was dissolved in thionyl chloride (34 mL).
The reaction vessel was equipped with reflux condenser and heated to 70°C for 22 h. The
resulting mixture was concentrated in vacuo at 70°C to remove excess thionyl chloride and
obtain 2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (7) as a yellow solid (2.27 g, quant yield):
m.p 147–149°C; 1H NMR (300 MHz, DMSO-d6) δ 9.33–9.31 (m, 1H), 8.83 (dd, J = 4.7, 1.4 Hz,

97

1H), 8.51 (d, J = 8.0 Hz, 1H), 8.19 (d, J = 7.8 Hz, 1H), 7.98 (app. t, J = 7.8, 1H), 7.76 (d, J = 8.1
Hz, 1H), 7.69–7.62 (m, 2H); 13C NMR (75 MHz, DMSO-d6) δ158.6, 155.1, 152.9, 148.6,
145.9, 136.9, 135.3, 128.9, 128.1, 127.0, 126.3, 124.0, 117.2; ESI-MS, m/z: 225 [m+H]+.

Figure 4-7. 13C-NMR Spectra of compound 7.
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Figure 4-8. 1H-NMR Spectra of compound 7.

3-(5-bromopyridin-2-yl)-2-(pyridin-3-yl)quinazolin-4(3H)-one:

2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (7) (0.30 g, 1.34 mmol) and 2-amino-5-bromopyridine (0.35 g, 2.00 mmol) was added to wet pyridine (2.5 mL) in a microwave vial. The vial
was sealed and heated at 200°C in a sand bath for 4 days. The resulting mixture was concentrated
in vacuo. Purification by column chromatography (50% Et2O/CH2Cl2) of the crude residue
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produced 3-(5-bromopyridin-2-yl)-2-(pyridin-3-yl)quinazolin-4(3H)-one (1) as a light yellow
foam (0.30 g, 58%): 1H NMR (300 MHz, CDCl3) δ 8.58 (d, J = 1.62 Hz, 1H), 8.52 (dd, J = 4.8,
1.4 Hz, 1H), 8.45 (d, J = 5.5 Hz, 1H), 8.33 (d, J = 7.8, 1H), 7.89 (dd, J = 8.4, 2.4 Hz, 1H), 7.86–
7.79 (m, 2H), 7.73 (dt, J = 7.9, 1.8 Hz, 1H), 7.58–7.53 (m, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.21
(dd, J = 7.8, 4.9 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 161.9, 151.6, 150.8, 150.4, 149.4,
149.3, 147.3, 141.0, 136.2, 135.4, 131.6, 128.1, 127.9, 127.3, 125.8, 123.0, 121.1, 120.0; HPLC
purity: RT = 10.1 min., 98% pure. ESI-MS, m/z: 379 [m+H]+.

Figure 4-9. 13C-NMR Spectra of compound 1.
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Figure 4-10. 1H-NMR Spectra of compound 1.

3-(4-methoxyphenyl)-2-(pyridin-3-yl)quinazolin-4(3H)-one:

2-(pyridin-3-yl)-4H-benzo[d][1,3]oxazin-4-one (7) (0.30 g, 1.34 mmol) and p-anisidine (0.25 g,
2.00 mmol) was added to wet pyridine (2.5 mL) in a microwave vial. The vial was sealed and
heated at 200°C in a sand bath for 4 days. The resulting mixture was concentrated in vacuo.
Purification by column chromatography (50% Et2O/CH2Cl2) of the crude residue produced 3-(4methoxyphenyl)-2-(pyridin-3-yl)quinazolin-4(3H)-one as a yellow film (0.32 g, 72%): Rf = 0.18

101

(20% Et2O/hexane); 1H NMR (300 MHz, CDCl3) δ 8.64 (br. s, 1H), 8.50, (d, J = 3.8 Hz, 1H),
8.35 (d, J = 8.0 Hz, 1H), 7.85–7.76 (m, 2H), 7.63 (dt, J = 8.0, 1.8 Hz, 1H), 7.58–7.52 (m, 1H),
7.17 (dd, J = 7.8, 4.9 Hz, 1H), 7.06 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 3.72 (s, 3H);
13C NMR (75 MHz, CDCl3) δ 162.4, 159.6, 152.9, 150.1, 149.8, 147.4, 136.3, 135.0, 131.9,
130.2, 129.8, 127.9, 127.8, 127.4, 122.8, 121.2, 114.7, 55.5. HPLC purity: RT = 9.3 min., 98%
pure. ESI-MS, m/z: 330 [m+H]+.

Figure 4-11. 13C-NMR Spectra of compound 2.
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Figure 4-12. 1H-NMR Spectra of compound 2.

Assay Development for Luciferase Inhibition

Luciferase inhibition by 4-quinazolinone compounds was addressed using an optimized
assay protocol. To address potential signal drift, reaction wells were prepared with no compound
and allowed to incubate for 30 min. The plate was immediately read. Two more measurements
were made 15 min. apart (figure 4-12). Results indicate the signal stabilizes between 45 and 60
min. relative to no ATP control. Initially, just the reference compounds were tested against the
luciferase within the detector reagent. Resveratrol and luciferase inhibitor 1 inhibited the enzyme
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at 14.8 µM and 9.1 µM, respectively (figure 4-14). A Z’ factor of 0.9 suggested excellent
separation and each point displayed no more than 5% coefficient of variation.

Figure 4-13. Luminescence signal with time. Triplicate wells were tested for signal drift at 30,
45, and 60 minutes. The 45-minute incubation period produced stable signal.
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Figure 4-14. Known luciferase inhibitors display luciferase inhibition.

A

B

Figure 4-15. Luciferase inhibitor IC50 curves. A) Resveratrol inhibits luciferase with an IC50 of
15 µM B) Luciferase inhibitor 1 potently inhibits luciferase activity with an exhibited IC50 of 9.1
µM.
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The luciferase inhibitor 1 and resveratrol compounds that were confirmed to inhibit
luciferase were used to evaluate 4-quinazolinone compounds 1 and 2. This screen evaluated
inhibition of the enzyme within a range of 0.1-200 µM of compound. As seen in figure 4-13,
reference compounds inhibited the luciferase at low micromolar ranges while the compounds in
question failed to show any effect. Statistical parameters were calculated to be 0.9 for Z’ and no
higher than 5% CV for all data points.

Figure 4-16. Luciferase with 4-quinazolinone compounds. No inhibition was seen with
compounds 1 and 2 against luciferase with adequate control reactions.
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A

B

Figure 4-17. Known luciferase inhibitor consistently affect Kinase-Glo luciferase. A)
Resveratrol inhibits luciferase with an IC50 of 10 µM B) Luciferase inhibitor 1 inhibits luciferase
with an IC50 of 4 µM. Each fit was fixed at zero percent inhibition.

The same screen was done to address inhibition of luciferase at higher concentrations of
inhibitor. It also served to evaluate reproducibility of the assay. This test was executed two
weeks after the initial screen with new reagent preparations at a wider concentration range
between 800-0.1 µM of inhibitor. As seen in figure 4-16, the reference compounds inhibit
luciferase with similar potency as before with an IC50 of 19 µM (resveratrol) and 25 µM (LI1)
while the 4-quinazolinone compounds showed no inhibition at 800 µM. Again, statistical
parameters were confirmed to comply within acceptable limits. Furthermore, this suggests plateto-plate variability will be low and reproducibility high for this luciferase inhibition assay.
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Figure 4-18. Reproducibility of luciferase inhibition screen. At a wider concentration range, all
control reactions compared to 4-quinazolinone compounds further confirmed that they do not
inhibit luciferase.
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A

B

Figure 4-19. Luciferase control compounds inhibit luciferase enzyme. A wider concentration
range accurately defines which concentration inhibits luciferase by 50%. A) Resveratrol
inhibition of luciferase B) Luciferase inhibitor 1 inhibition of luciferase. Each fit was fixed at
zero percent inhibition.

Assay Development for IspE Inhibition
The 4-quinazolinone compounds could in fact be IspE inhibitors as they did not inhibit
the luciferase enzyme. Consequently, an IspE inhibition assay using the Kinase-Glo™ Plus
luminescence kit was optimized for use. BtIspE was the only species evaluated in this study. As
described in chapter 2, buffer conditions that best stabilized BtIspE correlated with the ones used
in this pilot study to address enzyme inhibition. To evaluate compatibility of BtIspE and the
coupled enzyme luciferase with the DMSO, the activity, as determined by luciferase conversion
of left-over ATP was tested. DMSO is regularly used to promote solubility of inhibitors that are
incompatible with aqueous buffers. Results indicated that about 10% of activity was lost from
the exposure of the enzyme in 10% DMSO (figure 4-18).
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Figure 4-20. Effect of DMSO on BtIspE activity.

The next step was to verify the that the optimal amount of kinase and substrate used in
the protocol produced a suitable dynamic range. Also, substrate turnover should be slow enough
to enhance sensitivity for slow-binding inhibitors. To start, a titration curve was made to show
which concentrations exhibited luminescence signal within linear range. At this point, initial
velocity conditions hold and changes to the rate can be detected.101 Once determined, that
solution is tested at various substrate concentrations to verify turn-over is consistent to maintain
assay sensitivity. In other words, after the 45-min. incubation period, the luminescence signal
should increase with lower substrate concentrations as less ATP is turnover (figure 4-20). An
example of over-estimating which enzyme concentration to use can be seen in figure 4-19. The
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trend obtained with different concentrations of CDP-ME suggests non-linear substrate turnover.
At this concentration inhibition is difficult to detect.

B

A

Figure 4-21. Substrate turnover with high BtIspE concentration. A) BtIspE concentration
titration, red box indicates which concentration was used for inhibition assay B) Non-linear
(R2=0.42) substrate turn-over makes inhibition difficult to detect.

A

B

Figure 4-22. Substrate turn-over with optimal BtIspE used. A) BtIspE titration curve, red box
indicates which concentration was used for inhibition assay Signal is well within linear range
(R2= -0.93) for variable CDP-ME concentrations.

111

The enzyme concentration determined above was further used in the next development
stage, reference compound determination. As previously mentioned, compounds 3-6 in figure 42 were tested to see if they could serve as reference compounds for the IspE inhibition assay.
Prior to testing, kinetic parameters should be established for each enzyme. In this study, these
have yet to be determined. In turn, those compounds were still tested to see if the published
protocol confirmed these compounds showed inhibition against IspE. Initially, BtIspE was tested
against HGN-0779. The compound was tested at both the high and low concentrations of protein
seen if figure 4-22. Inhibition is detected only with lower kinase concentration (figure 4-21) and
estimated to be at 170 µM. When evaluated against higher concentrations of BtIspE, no
inhibition was seen.

A

B

Figure 4-23. BtIspE with HGN-0779 inhibition. A) Optimal vs non-optimal BtIspE
concentration used to estimated potency of HGN-0779 B) Optimal enzyme concentration
showed estimated inhibition at IC50 µM with fixed 100% inhibition at 1.0.

112

Furthermore, BtIspE was tested against HGN-0333. The exhibited IC50 was around 155 µM

A

B

Figure 4-24. BtIspE with HGN-0333 inhibition. The estimated potency of this compound was
found to be 155 µM at optimal protein concentrations. A) Inhibition data vs controls B) Fit
estimates IC50 value with fixed 100% inhibition at 1.0.

A reference compound inhibits the enzyme at a consistent concentration if it was to be
used as a control. Previous work on this project found that HGN-0779 inhibited BtIspE at 169
µM (unpublished result). This correlates well with the IC50 value obtained suggesting this
compound would work well as a control. On the other hand, inhibition data obtained for HGN0333 did not since it previously inhibited BtIspE at 24 µM (unpublished result). Validation
parameters were found to be well within limit with Z`= 0.9 and all CV at < 5% for all points.
Verification of Inhibitor Binding to IspE

The viability of the proposed reference compounds for the IspE inhibition assay were
evaluated using DSF and ITC. The 4-quinazolinone compounds in question were also tested.
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DSF results were obtained for EcIspE and BtIspE. As seen below in figure 4-23, a significant
negative shift is observed in EcIspE thermal melts with HGN-0333 or HGN-940, while
compounds 1 and 2 fails to significantly impact the stability of the enzyme in solution. The data
obtained for HGN-0333 to EcIspE did not show a well-defined transition curve. Hence, no Tm
was reported.
EcIspe screen

Compound (250 µM)
Control (No Compound)
HGN-0940
Compound 1
Compound 2

Tm
54.8 (±0.2)
51.2 (±0.1)
55.3 (±0.0)
55.5 (±0.4)

ΔTm
-3.6 (±0.2)
0.5 (±0.2)
0.7 (±0.4)

Figure 4-25. DSF compound screen with EcIspE. The compounds successfully tested are seen
above. HGN-0333 and HGN-0940 significantly effect EcIspE stability in solution.

Furthermore, the compound screen against BtIspE (figure 4-24) successfully evaluated 5
compounds. The reference compounds HGN-0779 and HGN-0333 negatively impacted enzyme
stability while the other compounds had no significant effect.
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Compound (250 µM)
Control (No Compound)
HGN-0333
HGN-0779
HGN-0940
Compound 1
Compound 2

Tm
42.6 (±0.1)
40.3 (±0.1)
39.1 (±0.4)
41.9 (±0.2)
42.0 (±0.7)
42.0 (±0.7)

ΔTm
-2.3 (±0.1)
-3.5 (±0.4)
-0.7 (±0.2)
-0.6 (±0.7)
-0.6 (±0.7)

Figure 4-26. DSF compound screen with BtIspE. The compounds successfully tested are seen
above. HGN-0779 and HGN-0333 significantly impacted BtIspE stability in solution while all
others only displayed minimal impact.

Further binding studies that used isothermal titration calorimetry suggested that HGN-0779
bound to BtIspE. (figure 4-25). The experiment with a fixed stoichiometric ratio at 1.0 (due to
weak binding), suggested the apparent dissociation constant was 6.3 µM. The ΔHº of HGN-0779
showed to have a value of -3.6 kcal/mol and an entropic contribution of -TΔS of -3.2 kcal/mol. It
is worth noting that post-titration, aggregation is observed after the titration is complete.
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Figure 4-27. ITC titration of BtIspE with HGN-0779. The conditions were held at pH 7.0 at
25°C.

Discussion

Discovering potential inhibitors against IspE is reliant on screening techniques. The basis
of such techniques is the development of a robust and reproducible assay. Previously determined
inhibition data of proposed IspE inhibitors containing a 4-quinazolinone core were reported as
irreproducible.51,52 Persch et al. hypothesized that that those compounds inhibit the auxiliary
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enzyme luciferase instead of IspE. Here, a luciferase-inhibition assay was developed to test that
idea. All statistical data suggested it was a well-prepared assay and the compounds in question
did not inhibit luciferase up to 800 µM concentrations. The reference compounds, luciferase
inhibitor 1 and resveratrol, which served as control luciferase inhibitors, consistently inhibited
the enzyme at a low micromolar ranges. If no inhibition was seen here, these compounds could
in fact inhibit IspE.
The initial study by Tidten-Luksch et al. that found these compounds to inhibit IspE, used
the Kinase-Glo® Plus luminescence kit from Promega with substrate concentrations at 3×Km.
Instead, this study addressed if these compounds inhibited IspE against lower substrate
concentrations. Published data has previously showed that EcIspE has a Km of either 150 µM and
200 µM for CDP-ME.40,49 To assess if the 4-quinazolinone compounds inhibited IspE
competitively, a protocol using 200 µM substrate was used. Before these compounds were to be
evaluated, reference compounds were needed as controls. Out of the two that were attempted,
HGN-0779 was reproducible with an IC50 value at ~160 µM. The other, HGN-0333, failed to
inhibit BtIspE at low micromolar ranges as previously reported. This suggests the former could
potentially be used as a reference control while the latter would not suffice. Further investigation
would be needed to address this discrepancy. With an established control, future work can
address IspE inhibition with the 4-quinazolinone compounds.
Differential scanning fluorimetry and isothermal titration calorimetry data suggested
some reference inhibitors destabilized IspE. As seen in the DSF results, HGN-0333, HGN-0779,
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and HGN-0940 negatively impacted the stability of both EcIspE or BtIspE. This data may be due
to allosteric binding that effects the structure of each enzyme. On the other hand, ITC
experiments showed favorable binding thermodynamics to BtIspE against HGN-0779. Notably,
BtIspE aggregated once ligand was injected into sample cell suggesting it destabilized the
enzyme. Furthermore, compound 1 and 2 neglected to show any inherent stabilizing effect on
either BtIspE nor EcIspE. These 4-quinazolinone compounds may not inhibit IspE as suggested
by Persch et. al. Future work entails further testing those compounds in competitive and noncompetitive assays directed towards substrate and co-factor binding sites of IspE.

Chapter 5

SUMMARY
The initial steps in early stage drug discovery of novel antibiotics is to identify a suitable
target that when inhibited prevents an important cellular process from functioning within
pathogenic organisms. The activity of the enzymatic target is then characterized for use in highthroughput screening techniques. The non-mevalonate (MEP) pathway was discovered in the
early 1990’s to produce isoprenoid pre-cursors that are utilized by numerous pathways to
produce life essential compounds.30 Prior to the discovery of that pathway, it was believed that
the mevalonate pathway, found in mammals, was responsible for IPP and DMAPP production in
bacteria. Further research indicated that in fact, no enzymes present in the mevalonate pathway
overlap with the non-mevalonate pathway. This makes the non-mevalonate pathway a good
pharmaceutical target. Numerous inhibitors targeting enzymes from the MEP pathway have been
discovered. Compounds inhibiting IspE have possessed generally weak potencies (IC50 values
low micromolar). To date, no inhibitors of the IspE enzyme have advanced to clinical trials. As
IspE catalyzes substrate phosphorylation, the ATP and CDP-ME binding sites within the active
site were targeted. Previous research focused on potent inhibitors designed to bind to the CDPME sub-site. To characterize these native interactions, this study aimed to better understand the
different functional groups of the substrate and co-factor and their energetic contributions
towards binding IspE. These studies also evaluated the stability of IspE in various conditions and
began assay development studies to address conflicting data published by two other groups.

119

The investigation that aimed to improve stability of IspE in vitro found optimal
conditions for each enzyme. Each species was positively influence by reducing conditions at a
higher ionic strength with the presence of Mg2+ ions. Furthermore, a high pH sensitivity was
observed with MaIspE thermal melts. The significant difference in secondary structure stability
with only minor changes in pH suggests an important electrostatic interaction holds a stable
conformation. CD experimentation found the most stable pH to be around 7.0.
The synthesis of an isotopically labeled substrate can be used in the future to study
kinetics and thermodynamic properties of substrate binding. The developed enzymatic synthesis
of isotopically labeled CPD-ME could be easily stopped or continued at different points along
the MEP pathway to obtain isotopically labeled substrate for all enzymes in the non-mevalonate
pathway. A significant stock of isotopically labeled CDP-ME has been generated and stored for
future investigations. Isothermal titration calorimetry and differential scanning calorimetry found
that the complete loss of phosphate groups on ATP showed no detectable binding to the IspE
enzyme. DSF displayed no change in melting temperature suggesting adenosine neither stabilizes
or destabilizes the enzyme. Furthermore, the most significant contribution in binding was
observed with CMP, highlighting the importance of the α-phosphate group of CMP in MaIspE
recognition. A 10°C shift in melting temperature suggests that this compound, CMP,
significantly stabilized the enzyme. Overall, these results, when related to published crystal
structures, indicate that the glycine-rich phosphate binding loop may be important in co-factor
binding while the presence or absence of substrate phosphate groups is not as detrimental.
Specifically, cytosine still binds to the enzyme. The residue SER147 in MaIspE seems to play an
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important role as a significant difference in stability and binding is observed when just the αphosphate is present. A full profile of all substrate and co-factor derivatives would further
indicate what other ligand – enzyme interactions are important.
High-throughput screening relies on highly reproducible and robust assays that are
validated through a rigorous set of guidelines. These assays are essential to any early stage drug
discovery project. A detailed assay protocol must be documented to promote reproducibility
day-to-day, plate-to-plate, and person-to-person. The 4-quinazolinone compounds were
synthesized to address conflicting results reported in the literature. The compounds were
synthesized with high purity. It was theorized that the 4-quinazolinone compounds inhibited the
auxiliary enzyme, luciferase, but when tested multiple times with a luciferase assay, the
compounds did not show inhibition at concentrations below 200 µM. Furthermore, the Kinase
Glo IspE inhibition assay was not able to reproduce published IC50 values for multiple reference
inhibitors. This assay development step is key in validating the assay. The DSF screen of IspE
evaluated both the reference compounds and the 4-quinazolinone compounds in question. All of
the compounds screened did not significantly stabilize IspE while some reference compounds
negatively impacted stability with ∆Tm values of -3.5 to -0.6 °C.
The initial study that reported 4-quinazolinone core compounds possessing low
micromolar inhibition of EcIspE used a high substrate concentration in comparison to what is
recommended for investigating competitive inhibitors. This could indicate the compounds bind
elsewhere other than the CDP-ME binding site. ATP competitive inhibition should be tested with
these potential inhibitors.
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This study evaluated stability of IspE in various environmental conditions, determined
important binding site interactions between substrate and co-factor, and successfully developed
an assay. The luciferase-based inhibition assay was used to confirm that 4-quinazolinone
compounds did not inhibit the auxiliary enzyme used in the reported IspE inhibition assay.
Further investigation is needed to determine if they in fact inhibit IspE at low micromolar ranges.
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Appendix A
Isotherm and Raw Data from Isothermal Titration Calorimetry Analysis of Co-factor and
Substrate Derivatives Against Burkholderia thailandensis IspE.
The compounds that were tested were AMP-PNP, ATP, ADP, AMP, adenosine, CDP, CMP, and
cytidine.
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Figure A1: Raw Data and isotherm of Burkholderia thailandensis IspE vs AMP-PNP
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Figure A2: Raw Data and isotherm of Burkholderia thailandensis IspE vs ATP
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Figure A3: Raw Data and isotherm of Burkholderia thailandensis IspE vs ADP
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Figure A4: Raw Data and isotherm of Burkholderia thailandensis IspE vs AMP
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Figure A5: Raw Data and isotherm of Burkholderia thailandensis IspE vs Adenosine
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Figure A6: Raw Data and isotherm of Burkholderia thailandensis IspE vs CDP
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Figure A7: Raw Data and isotherms of Burkholderia thailandensis IspE vs CMP
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Figure A8: Raw Data and isotherm of Burkholderia thailandensis IspE vs Cytidine

Appendix B
Isotherm and Raw Data from Isothermal Titration Calorimetry Analysis of Co-factor and
Substrate Derivatives Against Mycobacterium Abscessus IspE.
The compounds that were tested were ATP, ADP, AMP, adenosine, CDP, and CMP.
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Figure B1: Raw Data and isotherm of Mycobacterium Abscessus IspE vs ATP.
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Figure B2: Raw Data and isotherm of Mycobacterium Abscessus IspE vs ADP.
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Figure B3: Raw Data and isotherm of Mycobacterium Abscessus IspE vs AMP.
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Figure B4: Raw Data and isotherm of Mycobacterium Abscessus IspE vs Adenosine.
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Figure B5: Raw Data and isotherm of Mycobacterium Abscessus IspE vs CDP.
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Figure B5: Raw Data and isotherm of Mycobacterium Abscessus IspE vs CDP.

Appendix C
DNA and Protein Sequences of Escherichia coli IspE , Burkholderia thailandensis IspE,
Mycobacterium abscessus IspE, and Burkholderia thailandensis DXS
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Figure C1: Escherichia coli IspE DNA and protein sequence with C-Terminal 8xHIS-tag
highlighted in yellow.
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TTGCGTGAGAACGGCGATCCGCCGCGGCTCGCCGAGGCGGATGAGCTTTTGGGTGCGCTC
L R E N G D P P R L A E A D E L L G A L

721
241

730
740
750
760
770
780
GCCGCCGGGGACGCGCGCCGGCTGGCGCCGCTGCTCGGTAACGAATTGCAGGCCGCGGCG
A A G D A R R L A P L L G N E L Q A A A

781
261

790
800
810
820
830
840
GTCAGCCTGAACCCCGAATTGCGGCGCACGCTGCGGGCAGGGGAGTCGGCCGGCGCCCTG
V S L N P E L R R T L R A G E S A G A L

841
281

850
860
870
880
890
900
GCTGGAATCGTCTCCGGATCGGGCCCCACCTGTGCGTTCTTGTGCACCTCGGCCGACGAT
A G I V S G S G P T C A F L C T S A D D

901
301

910
920
930
940
950
960
GCGGTGCAGGTGAGTGCGGAGCTGGCGGGCGCGGGGGTGTGCCGCACCGTGCGGGTGGCC
A V Q V S A E L A G A G V C R T V R V A

961
321

970
980
990
1000
1010
AGCGGACCCGTGCACGGCGCACAGGTCATCCAGGGCCGCAGTGACGGCTAA
S G P V H G A Q V I Q G R S D G *

Figure C2: Burkholderia thailandensis IspE DNA and protein sequence with N-Terminal 6xHIStag highlighted in yellow.
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ATGGCTCATCACCATCACCATCATATGGGTACCCTGGAAGCTCAGACCCAGGGTCCTGGT
M A H H H H H H M G T L E A Q T Q G P G
-----HISTAG----70
80
90
100
110
120
TCGATGACCGATACGACCCGCTCGCTGCGCGACTGCCTCGCCCCGGCGAAACTGAACCTG
S M T D T T R S L R D C L A P A K L N L

121
41

130
140
150
160
170
180
TTCCTGCACATCACGGGCCGTCGTCCGGACGGCTATCACGAGCTGCAAAGCGTGTTCCAG
F L H I T G R R P D G Y H E L Q S V F Q

181
61

190
200
210
220
230
240
CTGCTCGACTGGGGCGACCGGCTGCACTTCACGCTGCGCGACGACGGCAAGGTGTCGCGC
L L D W G D R L H F T L R D D G K V S R

241
81

250
260
270
280
290
300
AAGACCGACGTGCCGGGCGTACCCGAGGAAACCGACCTCATCGTGCGCGCGGCGTCGCTG
K T D V P G V P E E T D L I V R A A S L

301
101

310
320
330
340
350
360
CTGAAAGCGCACACGGGCACGGCGGCGGGCGTCGACATCGAGATCGACAAGCGACTGCCG
L K A H T G T A A G V D I E I D K R L P

361
121

370
380
390
400
410
420
ATGGGCGCGGGCCTCGGCGGAGGCAGCTCGGATGCGGCGACGACGTTGCTCGCGCTCAAC
M G A G L G G G S S D A A T T L L A L N

421
141

430
440
450
460
470
480
CGCCTCTGGAAGCTCGACTTGCCGCGCGCCACGCTGCAATCGCTCGCGGTGAAGCTCGGC
R L W K L D L P R A T L Q S L A V K L G

481
161

490
500
510
520
530
540
GCCGACGTGCCGTTCTTCGTCTTCGGAAAAAATGCGTTCGCAGAGGGTATCGGAGAAGCG
A D V P F F V F G K N A F A E G I G E A

541
181

550
560
570
580
590
600
CTGCAAGCTGTAGAATTGCCGACTCGCTGGTTTCTGGTTGTGACACCGCGGGTTCACGTT
L Q A V E L P T R W F L V V T P R V H V

601
201

610
620
630
640
650
660
CCGACCGCAGCGATTTTTTCCGAAAAATCGTTGACAAGAGATTCGAAACCCATCACAATT
P T A A I F S E K S L T R D S K P I T I

661
221

670
680
690
700
710
720
ACGGACTTTCTTGCACAGCAAGACTGCAACACGGGATGGCCTGACAGTTTCGGTCGGAAT
T D F L A Q Q D C N T G W P D S F G R N

721

730
740
750
760
770
780
GACATGCAGCCGGTTGTGACAAGCAAGTACGCGGAAGTTGCAAAGGTGGTCGGATGGTTT

1
1
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241
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M

Q
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T

S
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Y
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E

V

A

K

V

V

G

W

F

781
261

790
800
810
820
830
840
TATAATCTGACCCCCGCGCGGATGACCGGCTCCGGAGCTAGCGTGTTTGCAGCGTTCAAG
Y N L T P A R M T G S G A S V F A A F K

841
281

850
860
870
880
890
900
AGCAAGGCGGAGGCAGGAGCGGCGCAAGCCCAACTGCCGGCCGGCTGGGACAGCGCAGTT
S K A E A G A A Q A Q L P A G W D S A V

901
301

910
920
930
940
GCCGAGAGCTTGGGTGAGCATCCACTCTTCGCTTTCGCGTCATAA
A E S L G E H P L F A F A S *

Figure C3: Mycobacterium abscessus IspE DNA and protein sequence with N-Terminal 6xHIStag highlighted in yellow.
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ATGGCTCATCACCATCACCATCATATGGGTACCCTGGAAGCTCAGACCCAGGGTCCTGGT
M A H H H H H H M G T L E A Q T Q G P G
-----HISTAG----70
80
90
100
110
120
TCGATGTACGACTTGCTGAAAACCATCGACGACCCGGCGGACCTGCGCCGTCTCGATCGT
S M Y D L L K T I D D P A D L R R L D R

121
41

130
140
150
160
170
180
CGCCAACTGCAGCCGCTCGCCGACGAGCTGCGCGCGTTCGTTCTCGACAGCGTGTCGAAG
R Q L Q P L A D E L R A F V L D S V S K

181
61

190
200
210
220
230
240
ACGGGCGGCCATTTGTCGTCCAATCTCGGCACGGTCGAGCTGACGATCGCGCTGCATTAC
T G G H L S S N L G T V E L T I A L H Y

241
81

250
260
270
280
290
300
GTGTTCAACACGCCGGACGACCGGATCGTGTGGGACGTCGGTCACCAGACCTATCCGCAC
V F N T P D D R I V W D V G H Q T Y P H

301
101

310
320
330
340
350
360
AAGATCCTGACGGGCCGCCGCGACGGGATGAAGACGCTGCGCCAGTTCGACGGCATCTCG
K I L T G R R D G M K T L R Q F D G I S

1
1

370

380

390

400

410

420

146

361
121

GGCTTTCCGCGCCGCTCGGAATCCGAATACGACACGTTCGGCACCGCGCACTCGAGCACG
G F P R R S E S E Y D T F G T A H S S T

421
141

430
440
450
460
470
480
TCGATCTCGGCTGCGCTCGGGATGGCGATCGGCAGCAAGCTGAACGGCGACGACCGCTTC
S I S A A L G M A I G S K L N G D D R F

481
161

490
500
510
520
530
540
TCGATCGCGGTGATCGGCGACGGCGCGATGACGGCCGGCATGGCGTTCGAGGCGATGAAC
S I A V I G D G A M T A G M A F E A M N

541
181

550
560
570
580
590
600
AACGCGGGCGTGTCCGAGGACGCGAAGCTCCTCGTGATCCTGAACGACAACGACATGTCG
N A G V S E D A K L L V I L N D N D M S

601
201

610
620
630
640
650
660
ATCTCGCCGCCCGTCGGCGCGCTGAACCGCCATCTCGCGCGCCTGATGTCGGGCCGCTTC
I S P P V G A L N R H L A R L M S G R F

661
221

670
680
690
700
710
720
TACGCGGCCGCGCGCGCGGGCGTCGAACGCGTGCTGAGCGTCGCGCCGCCCGTGCTCGAG
Y A A A R A G V E R V L S V A P P V L E

721
241

730
740
750
760
770
780
CTCGCGCGCAAGCTCGAGGAGCATGCGAAGGGCATGGTGGTGCCCGCGACGCTCTTCGAG
L A R K L E E H A K G M V V P A T L F E

781
261

790
800
810
820
830
840
GAATTCGGCTTCAACTACATCGGGCCGATCGACGGCCACGATCTCGATTCGCTGATCCCG
E F G F N Y I G P I D G H D L D S L I P

841
281

850
860
870
880
890
900
ACGCTGCAGAACATCAAGGAACTGCGCGGCCCGCAGTTCCTGCACGTCGTGACGAAGAAG
T L Q N I K E L R G P Q F L H V V T K K

901
301

910
920
930
940
950
960
GGACAGGGCTACAAGCTCGCTGAGGCCGATCCGGTGCTCTATCACGGGCCCGGCAAGTTC
G Q G Y K L A E A D P V L Y H G P G K F

961
321

970
980
990
1000
1010
1020
AACCCGGCGGAAGGCATCAAGCCGTCCGCGACGCCGGCGAAGAAGACCTACACGCAGGTA
N P A E G I K P S A T P A K K T Y T Q V

1021
341

1030
1040
1050
1060
1070
1080
TTCGGCGAATGGCTGTGCGACGCGGCGGAGCTCGATGCGCGCGTGGTCGGCATCACGCCC
F G E W L C D A A E L D A R V V G I T P

1081
361

1090
1100
1110
1120
1130
1140
GCGATGCGCGAAGGCTCGGGCATGGTCGAGTTCGAGAAGCGCTTCCCGGAGCGCTACTAC
A M R E G S G M V E F E K R F P E R Y Y

147

1141
381

1150
1160
1170
1180
1190
1200
GACGTCGGCATTGCCGAGCAGCACGCGGTGACGTTCGCGGGCGGCCTCGCGACGGAAGGG
D V G I A E Q H A V T F A G G L A T E G

1201
401

1210
1220
1230
1240
1250
1260
CTCAAGCCCGTCGTCGCGATCTACTCGACTTTCCTGCAGCGCGCCTATGATCAGCTGATT
L K P V V A I Y S T F L Q R A Y D Q L I

1261
421

1270
1280
1290
1300
1310
1320
CACGACGTCGCGCTGCAGAACCTGCCCGTCGTGTTCGCGATCGATCGCGCGGGCCTCGTC
H D V A L Q N L P V V F A I D R A G L V

1321
441

1330
1340
1350
1360
1370
1380
GGCGCGGACGGCGCGACGCATGCGGGCGCATACGATCTCGCATTCCTGCGCTGCATCCCG
G A D G A T H A G A Y D L A F L R C I P

1381
461

1390
1400
1410
1420
1430
1440
AACATGACGGTGATGGCCGCGTCGGACGAGAACGAGTGTCGCCAGATGCTGCACACCGCG
N M T V M A A S D E N E C R Q M L H T A

1441
481

1450
1460
1470
1480
1490
1500
CTGCAGCAGCCGAACCCGACCGCGGTCCGTTATCCGCGCGGCGCAGGCACGGGCGTTGCG
L Q Q P N P T A V R Y P R G A G T G V A

1501
501

1510
1520
1530
1540
1550
1560
ACCGTCAAGGCGTTCACCGAGATTCCGCTCGGCAAGGGCGAAGTGCGCCGTCGCACGTCG
T V K A F T E I P L G K G E V R R R T S

1561
521

1570
1580
1590
1600
1610
1620
CAGCCGGACGGCAAGCGCGTCGCGATTCTCGCGTTCGGCACGATGGTCGCGCCGTCGCTT
Q P D G K R V A I L A F G T M V A P S L

1621
541

1630
1640
1650
1660
1670
1680
GCGGCCGCCGACGCGCTCGACGCGACCGTGGCGAACATGCGTTTCGTGAAGCCGATCGAC
A A A D A L D A T V A N M R F V K P I D

1681
561

1690
1700
1710
1720
1730
1740
GCCGAGCTCGTTCGAGAGCTCGCGCAGACGCACGACTACCTCGTCACCGTCGAGGAAGGC
A E L V R E L A Q T H D Y L V T V E E G

1741
581

1750
1760
1770
1780
1790
1800
TGCGTGATGGGCGGCGCGGGCTCCGCGTGCGTCGAGGCGATGATGGAAGGCGGCGCGGTC
C V M G G A G S A C V E A M M E G G A V

1801
601

1810
1820
1830
1840
1850
1860
CGTCCGGTGCTGCAGCTCGGCCTGCCGGACCGCTTCGTCGATCACGGCGATCCGGCGAAG
R P V L Q L G L P D R F V D H G D P A K
1870

1880

1890

1900

1910

1920

148

1861
621

CTGCTTGCGATGTGCGGTCTCGACGGCGATGGCATCGCGAAATCGATTCGCGAGCGCTTC
L L A M C G L D G D G I A K S I R E R F

1921
641

1930
1940
1950
1960
CTGAACCACGCGGCGAACGTCGCGAGTCCGGCGAAGCGCGTCGCATAA
L N H A A N V A S P A K R V A *

Figure C4: Burkholderia thailandensis DXS DNA and protein sequence with N-Terminal
6xHIS-tag highlighted in yellow.

